miRNA modules for precise, tunable control of gene expression

Rongrong Du*[1], Michael J. Flynn*[1], Karan Mahe[1], Monique Honsa[2], Bo Gu[1], Dongyang Li[1], Sean E. McGeary[3], Viviana Gradinaru[1], Ralf Jungmann[2], Michael B. Elowitz[1†]

*These authors contributed equally to this work
[†]correspondence: melowitz@caltech.edu

[1]Howard Hughes Medical Institute and Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA

[2]Max Planck Institute of Biochemistry, Martinsried, Germany; Faculty of Physics, Ludwig Maximilian University, Munich, Germany

[3]Department of Systems Biology, Harvard Medical School, Boston, MA, USA

Abstract

Accurate control of transgene expression is important for research and therapy but challenging to achieve in most settings. miRNA-based regulatory circuits can be incorporated within transgenes for improved control. However, the design principles, performance limits, and applications of these circuits in research and biotechnology have not been systematically determined. Here, combining modeling and experiments, we introduce miRNA-based circuit modules, termed DIMMERs, that establish precise, tunable control of transgene expression across diverse cell types to facilitate imaging, editing, and gene therapy. The circuits use multivalent miRNA regulatory interactions to achieve nearly uniform, tunable, protein expression over two orders of magnitude variation in gene dosage. They function across diverse cell types, and can be multiplexed for independent regulation of multiple genes. DIMMERs reduce off-target CRISPR base editing, improve single-molecule imaging, and allow live tracking of AAV-delivered transgene expression in mouse cortical neurons. DIMMERs thus enable accurate regulation for research and biotechnology applications.

One sentence description: Compact synthetic miRNA-based regulatory circuits enable tunable, orthogonal, and generalizable dosage-invariant gene expression control for diverse applications in research and biotechnology.

Introduction

Biomedical research and biotechnology heavily rely on expression of transgenes in living cells. The ability to accurately establish transgene expression at desired levels is critically needed in many contexts. For example, in gene therapy, overexpression of therapeutic transgenes can be toxic[1]. Similarly, in gene editing and imaging applications, overexpression can reduce specificity or increase background, respectively. However, popular expression systems, including DNA transfection and AAV vectors, as well as integrating systems such as lentivirus[2] or piggyBac transposons[3], typically generate a broad range of expression levels, due to variability in the number of gene copies taken up, integrated, and expressed by each cell, as well as gene expression noise[4,5]. Selecting individual stable clones can reduce variability, but is time-consuming and impossible for gene therapy.

What is needed is a simple gene regulation system that could compensate for unavoidable variation in delivery and expression (**Figure 1A**). The ideal system should have several key features: First, it should be genetically compact for compatibility with most delivery vectors. Second, it should allow predictive tuning of the expression setpoint. Third, it should permit construction of multiple independent (orthogonal) regulation systems for simultaneous control of multiple genes. Finally, it should operate across multiple cell types (portability) (**Figure 1B**).

The incoherent feed-forward loop (IFFL) circuit motif provides an ideal foundation for these capabilities[6]. A circuit in which a target gene and its negative regulator are both encoded in the same DNA construct represents an IFFL-like configuration in which gene dosage, considered as an input, modulates expression of both the target and its negative regulator. When these effects effectively cancel out, target expression can asymptotically approach a constant expression level independent of gene dosage (**Figure 1C, Supplementary Modeling Text**).

Previous studies have introduced synthetic circuits based on this principle. Bleris et al. showed that an IFFL based on microRNA (miRNA hereafter) as the negative regulator could achieve dosage compensation[7]. Strovas et al. introduced a similar design incorporating a natural miRNA and multiple repeats of its binding site within the target gene, and examined its expression dynamics over several days[8], achieving dosage compensation over a ~20-fold range at the cost of potential crosstalk with endogenous genes. Yang et al later introduced an “equalizer” architecture that combined transcriptional negative feedback through the TetR protein with feed-forward miRNA regulation[9]. This generated an extended regime of strong dosage compensation, but required expression of a bacterial protein. Tradeoffs between circuit complexity and efficiency are worth exploring further. Finally, while this work was under review, Love et al demonstrated other configurations of miRNA-based IFFL circuits for dosage compensation[10]. Nevertheless, fundamental questions have remained unclear: What sequence and circuit design principles optimize dosage compensation? Can these systems allow expression tuning, multiplexing of independent regulatory systems in the same cell, and portability across cell types and delivery modalities? And, can they provide durable control in vivo for gene therapy applications?

To address these goals, we combined mathematical modeling, synthetic design, and quantitative circuit analysis to create a set of miRNA-based dosage compensation systems

termed DIMMERs (Dosage Invariant miRNA-Mediated Expression Regulators). These circuits take advantage of multivalent miRNA regulation through the natural TNRC6 scaffold system[11]. They allow systematic tuning of expression levels by modulating the number of miRNA cassettes, numbers of target binding sites, and miRNA-target site complementarity. Further, they can be used to orthogonally regulate multiple genes in the same cell, and operate similarly across different cell types. A toolkit of ten mutually orthogonal ready-to-use expression systems can be incorporated into diverse systems. They facilitate biological imaging, improve CRISPR base editing, and function in vivo to allow AAV gene therapy applications. DIMMERs should thus allow routine research and biotechnology applications to operate with greater precision, control, and predictability.

Results

A minimal model shows that dosage compensation requires linear sensitivity to miRNA

To guide the design of DIMMERs, we first developed a minimal model of a miRNA-based IFFL circuit. This model makes several assumptions: (1) Primary miRNA (pri-miRNA) and target mRNA are each transcribed constitutively at a fixed ratio of rates, and in direct proportion to gene dosage. (2) There is a constant total rate, per gene copy, of RISC complex production, reflecting the combined process of pri-miRNA transcription, post-transcriptional processing, and binding to Argonaute proteins[12]. (3) RISC and its target mRNA bind reversibly to form a RISC-mRNA complex. Finally, (4) formation of this complex leads to degradation of the bound mRNA.

In certain regimes, this model exhibits dosage-invariant expression profiles, in which target protein expression levels increase linearly and then asymptotically approaches a dosage independent limiting expression level (**Figure 1D**). Several parameters modulate the limiting expression level while preserving asymptotic dosage compensation. These include the binding and unbinding rates of mRNA to miRNA, and the catalytic rate of mRNA degradation (**Figure S1A and B**). Accessing the dosage compensation regime requires that mRNA levels be linearly sensitive to RISC concentration (**Supplementary Modeling Text, Figure S1C**). Below, a more detailed model in which the total amounts of free and bound mRNA were also considered, revealed that miRNA-dependent catalytic degradation rates must exceed a minimal value for the total mRNA to show dosage invariance (**Supplementary Modeling Text, Figure S1D**). Together, these results suggest conditions in which miRNA-based IFFL circuits could produce gene dosage invariant expression.

Multimerization of weak target sites provides dosage compensation

Based on these results, we designed an initial set of regulatory circuits. Briefly, a synthetic miRNA and a target mRNA were placed in opposite orientations relative to a central divergent promoter[7] (**Figure 1E**). In one orientation, a previously characterized synthetic miRNA (miR-L, based on a Renilla luciferase sequence[13]) was co-expressed with the fluorescent protein mRuby3, serving as a dosage indicator. The miRNA expression cassette included the miR-E backbone for pri-miRNA expression[13] and was incorporated within a synthetic intron[14]. In the opposite orientation, we inserted a constitutively expressed EGFP target gene, with a single fully complementary 21-nt miRNA target site in the 3'-UTR. This

format allowed analysis of multiple miRNA and target site configurations, and independent modulation of miRNA and target gene expression levels. We also systematically analyzed a broad variety of other architectures (**Figure S2, Table S2**).

To quantitatively measure the behavior of the circuit, we transfected U2OS cells with each circuit construct, and analyzed expression by flow cytometry 48h later. We then plotted target EGFP expression versus gene dosage, indicated by mRuby3 fluorescence (**Figure 1F**). Compared to an unregulated control with no miRNA target site, the circuit strongly reduced target EGFP expression by 1–2 orders of magnitude. However, it failed to achieve dosage compensation (**Figure 1F**). We also analyzed similar circuits in which the complementary region was systematically reduced in single nucleotide increments from 21nt to 17nt. Constructs with 19 or 20nt sites retained repression but failed to produce dosage compensation, while shorter sequences lost repression altogether (**Figure 1G**). Thus, single target sites with varying levels of complementarity did not provide dosage compensation.

Native miRNAs are known to use much shorter complementary regions, including central mismatches (bulges)[12], and multivalent interactions mediated by TNRC6 scaffold proteins[11,15]. Therefore, we next considered designs with reduced complementarity and multimerized target binding sites. Tandem repeats of two to four copies of the 17nt target site, which was inactive in a single copy, progressively increased regulation (**Figure 1H**). More importantly, they successfully reduced dosage sensitivity, particularly at higher expression levels (**Figure 1H,I**). Thus, 4 tandem 17nt sites yielded only a ~4-fold change in expression over a ~200-fold range of dosages (**Figure 1I**). We also tested tandem repeats of two to four copies of the 18nt and 19nt target binding sites. Interestingly, the 18nt target site showed dosage compensation behavior at 3 copies, while the 19nt target site exhibited dosage compensation with only 2 copies (**Figure S3A, B**). “Bulged” target sites that provided no regulation individually nevertheless exhibited strong regulation and limited dosage compensation when multimerized (**Figure S3C, D**). These results indicate that multiple tandem copies of individually weak target sites can achieve dosage compensation over broad dosage regimes, at varying setpoints.

TNRC6 and Ago2 play key roles in regulation of multimerized 17nt targets

Why do multimerized weak sites produce better dosage compensation than stronger individual target sites? We reasoned that the TNRC6 scaffold protein could facilitate inhibition of multimerized weak target sites. To test whether regulation of multimeric weak sites requires TNRC6, we expressed T6B, a previously identified TNRC6B protein fragment that competitively inhibits TNRC6 activity (**Figure 2A**)[16]. T6B abolished regulation by a co-transfected 4×17nt DIMMER (**Figure 2B**), but had little effect on the single fully complementary 21nt construct (**Figure 2C**). As expected, negative controls using a T6B variant lacking the Ago2-binding domain failed to abolish regulation (**Figure S3E**). Interestingly, overexpression of wild-type Ago2 exhibited similar effects as ectopic T6B expression, nearly eliminating regulation in the 4×17nt case (**Figure 2D**), without affecting the 1×21nt configuration (**Figure 2E**), possibly due to sequestration of TNRC6. Thus, TNRC6 activity is required for regulation of the multimeric 4×17nt target, but not the single fully complementary site.

Although Ago2 predominantly directs repression through a slicing-independent mechanism, slicing occurs in at least a dozen complementary targets[17], and is required for maturation of two erythroid miRNAs that undergo non-canonical biogenesis[18]. To understand whether slicing activity is required for dosage compensation, we ectopically expressed a dominant negative Ago2 mutant (D669A) lacking slicing activity. This perturbation reduced regulation of both fully complementary and multimerized partially complementary targets (**Figure 2F,G**), suggesting that Ago2 slicer activity is required for repression of both targets. Further, to test for a role in cleavage of passenger strands, we incorporated a mismatch at 10-11nt in the original miRNA design (**Figure 2H**) in order to eliminate the requirement for Ago2 cleavage in miRNA maturation[18]. Inclusion of the mismatch slightly enhanced regulation of both the 4×17nt and 1×21nt (**Figure S3K, L**), possibly by elevating the efficiency of miRNA biogenesis. Although passenger strand removal is not required in this case, dominant negative Ago2 expression nevertheless largely eliminated regulation of both targets, consistent with a role for Ago2-dependent slicing in target repression (**Figure 2I-J**). By contrast, wild-type Ago2 overexpression had a partial impact on the 4×17nt target but no impact on the 1×21nt target (**Figure 2I-J**). We also analyzed other target sequences. The 4×18nt and 4×19nt targets responded similarly to T6B and $Ago2^{DN}$, with $Ago2^{DN}$ showing a slightly stronger de-repression effect. By contrast, wild-type Ago2 had weaker or no suppressive effect on these stronger target sites (**Figure 2K-L**), possibly because their longer complementary regions were less sensitive to indirect sequestration of TNRC6. Taken together, these results suggest that TNRC6 is required for repression of multimerized partially complementary targets but not fully complementary targets, and that Ago2-dependent slicing is required for repression of partially and fully complementary targets.

Taken together, these results suggest a potential explanation for why dosage compensation requires multimerized weak binding sites and TNRC6 (**Figure 2M**). Briefly, fully complementary binding sites are known to produce much more efficient slicing than partially complementary sites[19]. The fully complementary 21nt target could therefore produce dosage compensation at dosages and setpoints comparable to or lower than detection limits in the flow cytometry experiments. At the same time, the higher affinity of fully complementary binding sites would shift the “tail” of elevated expression due to bound-but-not-yet-degraded complexes to lower dosages. These combined effects could together explain the shape of the single 21nt fully complementary construct (**Figure 1F**). By contrast, constructs with multimerized weak binding sites (e.g. 4×17nt) would engage at higher gene dosages due to the lower intrinsic RNA affinity. This would lead to elevated setpoints and shift the “tail” of non-compensated expression to correspondingly higher dosages (**Figure 1I, Figure S1D**). Efficient mRNA degradation could be achieved by enhancing the intrinsically weaker Ago2-dependent slicing activity through stabilization of Ago2-mRNA complexes by TNRC6 and through TNRC6-dependent deadenylation, as described previously.

Dosage-invariant expression levels can be tuned

Having demonstrated dosage invariant circuit designs and gained insight into their design from the model, we next sought to identify experimentally tunable parameters that modulate expression level setpoints (**Figure 1E**). We first examined varying the length of target complementarity from 8 to 21nt, while maintaining 4 tandem repeats (**Figure 3A, Figure S4**). Repression was modest at 8nt, diminished with increased complementarity in the central region, and then strengthened again as more complementarity was added after the central

region (**Figure 3A,** left panel). These results are consistent with previous observations that miRNA inhibition does not increase monotonically with complementarity[20,21,22]. For the miR-L target site, repression was most sensitive at 16-20 nucleotides of complementarity (**Figure 3A**). Three designs—4×17, 4×18, and 4×19— achieved dosage invariant expression, but did so at distinct setpoints spanning more than an order of magnitude in saturating expression level (**Figure 3B**). These results indicate that site length can tune setpoint.

We next varied the number of copies of the miRNA expression cassettes in the synthetic intron, effectively modulating the stoichiometric ratio of miRNA to mRNA (**Figure 3C**). Compared to a single copy, two or three copies of the miRNA reduced expression by 2-fold and 3-fold, respectively, while preserving dosage compensation, providing a means of fine-tuning expression control.

We also compared different promoters to vary transcription of the miRNA and target cassettes. For the miRNA the weaker PGK promoter allowed ~3.5-fold more target gene expression at a given dosage level compared to the stronger EF1α, but nevertheless preserved dosage compensation (**Figure 3D**). Finally, we incorporated a tetracycline-responsive system (**Figure 3E**). This allowed setpoint tuning over ~2 orders of magnitude while preserving dosage compensation (**Figure 3E, Figure S5**). Taken together, these results demonstrate that dosage invariance can be preserved while allowing multiple mechanisms of coarse (site length, target transcription rate) and fine (miRNA promoter and copy number) setpoint tuning.

Orthogonal dosage compensation circuits allow independent control of target genes

Engineered genetic systems increasingly require multiple genes and transcripts, provoking a need for multiple independent DIMMER systems based on orthogonal synthetic miRNA-target site pairs, which we term *synmiRs*. To design synmiRs, we started by generating five random miRNA sequences, labeled synmiR1-5. Each sequence contained A at position 1 in the miRNA, a cognate U at the 3' end of a single target site and 25% GC content, similar to the structure of miR-L. We used an "open loop" system to analyze their behavior, allowing independent control of miRNA expression and measurement of its effect on a target miRNA reporter gene (**Figure 4A**). For a single fully complementary miR-L site, inhibition increased with miRNA dosage (**Figure 4B**), consistent with the earlier closed loop results (**Figure 1F**). synmiRs 1,4, and 5 repressed by at least an order of magnitude relative to a control lacking the miRNA (**Table S1, Figure 4D, Figure S7A**). By contrast, synmiRs 2 and 3 achieved weaker repression, possibly due to subsequences containing two or more A/T pairs in the extensive region, which could destabilize the miRNA[23,24] (**Figure S6A**). Consistent with this hypothesis, an A to G substitution at position 20 in synmiR-2 or at position 19 in synmiR-3 restored miRNA inhibition of target gene expression (**Figure 4D, Figure S7A**).

Based on these results, we formulated an empirical algorithm for synmiR design. Briefly, we generate random 21nt candidate miRNA sequences in which the mature miRNA (1) includes a 5'-U, based on known requirements for miRNA loading[12,25], and, (2) includes 5–8 G or C nucleotides, with 1–4 of them in the seed region, and 1–2 in the extensive region (**Figure 4C**). We synthesized five candidate sequences (synmiRs 6-10) based on this simple algorithm and analyzed their open loop behavior (**Figure 4D**, **Figure S6B**). All five sequences generated strong repression as single sites, comparable to that of miR-L. (One

sequence, synmiR-6, was discarded due to its similarity to the human endogenous miRNA hsa-mir-5697 (**Methods**)). Altogether, these results produced ten miRNA sequences capable of strong repression in their fully complementary form (**Figure 4D, Figure S7A**). Pairing each of these ten miRNAs with all ten of the target sequences in the open loop system revealed strong orthogonality in regulation, as desired (**Figure 4E, Figure S6C**).

Using these synmiR sequences, we developed a set of ten orthogonal dosage compensation circuits, using the framework in **Figure 1E**. Each of these sequences could produce dosage compensation in some configurations and dosage regimes. For example, with synmiR-4 and synmiR-5, the 4×17nt configuration produced a strong inhibition profile more similar to the fully complementary target (**Figure S6D**). We reasoned that this could reflect higher GC content in the seed and supplementary regions of these two miRNAs compared to miR-L, allowing shorter 8 or 9 nt target sites, present in 4-8 repeats, to produce dosage compensating designs (**Figure 4F**). In a similar way, we identified dosage compensation regimes for the other sequences (**Figure 4F**). Eventually, we identified nine DIMMER circuits exhibiting different levels of dosage compensation, of which five showed at least a 30-fold dosage-invariant range (**Figure 4F, Figure S7B**). Further, expression levels in these circuits were sensitive to the number and complementarity of target sites, allowing setpoint tuning (**Figure S8A**). With one exception, like the circuits above, these designs relied TNRC6 for dosage compensation (**Figure S8B**). The exception was synmiR-2 8×8nt, which maintained strong repression even under the T6B perturbation (**Figure S8B**). Taken together, these results provide a toolkit of dosage compensating systems and, more generally, suggest that it should be relatively feasible to engineer many additional dosage compensating systems with varying expression setpoints.

With multiple dosage compensation systems, it should be possible to independently specify the expression of multiple target genes in the same cells (**Figure 1B, panel 2**). To test this possibility, we constructed a second set of dosage compensation expression systems using distinct fluorescent reporters (**Figure 4G**). We transfected cells with pairs of systems that had different regulatory setpoints, and analyzed the resulting expression profiles of the two regulated target genes (**Figure 4H, Figure S6E**). Altogether, we analyzed four pairs of systems. Each produced a distinct two-dimensional expression distribution based on the setpoints for the two reporters (**Figure 4H**). By contrast, the unregulated group showed higher setpoints, and broader distributions of both reporters. The dosage indicators also exhibited the same distributions among all groups. Interestingly, the circuits allowed precise control of the stoichiometry of the regulated proteins (**Figure S6E**). The engineered dosage compensation systems thus make it possible to specify two-dimensional expression distributions, and suggest that control of higher dimensional distributions of more genes should also be accessible.

Dosage compensation systems are portable and minimally perturbative

An ideal dosage compensation system would be portable, able to operate similarly across different cell types, function in both transient transfection and genomic integration, and minimally perturb the host cell. To examine these features, we transiently transfected several circuit variants, including the 4×17nt miR-L system (**Figure 1H**), in four mammalian cell lines: U2OS[26], CHO-K1[27], HEK293[28], and N2A[29]. In each cell line, we observed strong and qualitatively similar dosage compensation (**Figure 5A**). Cell lines varied in the threshold

dosage at which expression saturated (**Figure 5A**, gray vertical line), and in the saturating expression level (**Figure 5A**, gray horizontal line), as measured in arbitrary fluorescence units. However, the ratio of these values was conserved (**Figure 5B**). We obtained similar results for other circuits as well, including synmiR-4, with 8 repeats of a 9nt target site, as well as both synmiR-L and synmiR-5, each with 8 repeats of an 8nt target site (**Figure S9A**). Again, the ratio of the saturating expression level to the threshold dosage was similar, for each construct, across cell lines (**Figure S9B**). This suggests a model in which the miRNA circuit functions equivalently in different cell types, but protein expression strengths vary, possibly due to differences in translational capacity or basal protein degradation rates[30–33]. Together, these results indicate that the dosage compensation circuits can function across different cell contexts.

Stable cell lines are important in research as well as applications like cell therapy. To find out whether dosage compensation circuits could also function in a stable integration context, we used PiggyBac transposition together with the iON system that allows expression only from constructs that have successfully integrated in the genome and undergone site-specific recombination[34]. We then selected mono-clones, and analyzed reporter expression by flow cytometry (**Figure 5C**). Integration copy numbers varied among clones by over two orders of magnitude, as indicated by mRuby3 fluorescence intensity (**Figure 5D left panel**, x-axis). Nevertheless, the cargo EGFP expression remained nearly constant (**Figure 5D left panel,** y-axis). By contrast, the unregulated mono-clones exhibited an apparent correlation between the integrated copy numbers and the EGFP expression (**Figure 5D right panel**). Thus, dosage compensation circuits function in stable integration settings.

The expression of synthetic miRNAs could in principle perturb endogenous gene expression. To identify such effects, we performed bulk RNA sequencing on cells transfected with miR-L and each of the 9 orthogonal synmiRs, and compared them to a negative control transfection of a BFP expression vector. Only a few genes were significantly up- or down-regulated by the miRNA (**Figure 5E**). These were enriched for heat shock proteins such as HSPA6. Critically, the gene sets up-regulated by different miRNAs exhibited strong overlap (**Figure 5F**, **Table S3, Figure S10**). Thus, for the synmiRs described here, off-target regulation appears to only reflect non-specific effects of miRNA expression, rather than sequence-specific perturbations.

Dosage compensation enhances biological imaging

Single-molecule imaging approaches such as DNA-PAINT (Point Accumulation for Imaging in Nanoscale Topography) often rely on ectopic expression of tagged proteins[35], which can dramatically exceed endogenous expression, distorting subcellular localization patterns. DIMMER circuits could potentially address this issue by limiting ectopic protein expression.

To test this, we transfected a DIMMER-regulated and unregulated EGFR-mEGFP membrane marker fusion protein expression-constructs into CHO-K1 cells, which lack endogenous EGFR expression[36] (**Figure 6A**). The DIMMER circuits successfully reduced expression, as measured by receptor density relative to an unregulated control, by at least 10-fold, as estimated from flow cytometry and confocal imaging (**Figure S11A-C**). To quantify this reduction more directly, we imaged transfected cells 48h post-transfection using the DNA-PAINT method, based on DNA-conjugated anti-GFP nanobodies targeting the

intracellular mEGFP tag of the EGFR receptor (**Figure 6B-D**). Circuit-regulated receptor mean densities were ~15-47 times lower than unregulated receptors (**Figure 6E, Figure S11D**). Further, expression distributions were narrower for the regulated plasmids compared to the unregulated ones (**Figure 6E**). Critically, DIMMER reduced expression more homogeneously than possible by simply reducing the concentration of unregulated plasmids in transfections (**Figure 6F**, **Figure S11D**). DIMMER-regulated expression with the 4×17nt circuit achieved EGFR expression levels comparable to but lower than those of wild-type U2OS cells. Thus, DIMMER circuits allow homogeneous reduction in ectopic expression to endogenous levels.

CRISPR imaging methods enable analysis of specific genomic loci in cell nuclei, but can be limited by high background fluorescence due to basal expression of dCas9 fluorescent protein fusions[37,38]. DIMMER circuits also improved dCas9-EGFP imaging of telomeres. We transfected dCas9-EGFP with or without DIMMER circuits, along with a gRNA targeting repetitive telomeric sequences[38–40] (**Figure 6G**). The circuits reduced dCas9-EGFP expression, and its dosage sensitivity (**Figure S12A**). Critically, in the unregulated system, dCas9-EGFP formed bright aggregations in the nucleolus, but seldom labeled the telomeres, consistent with previous observations[41] (**Figure 6H left panel**). By contrast, the 4×17nt circuit restricted most fluorescence to puncta (dots), consistent with telomeric labeling[38–40], and reduced labeling of the nucleolus (**Figure 6H middle panel**). Further, the stronger 4×19nt circuit removed nearly all labeling in the nucleolus, while maintaining apparent telomere labeling (**Figure 6H right panel**). DIMMER circuits also substantially improved signal-to-background ratio as well as contrast for individual dots (**Figure S12B**). Taken together, these results demonstrate that dosage compensation circuits can improve imaging of proteins and subcellular structures.

DIMMER reduces off-target RNA base editing and transcriptome stress

The adenine base editor ABEMax is a powerful gene-editing tool. However, it can induce undesired transcriptome-wide off-target A-to-I editing in HEK293 cells[42] and cause detrimental transcriptional responses[43], raising concerns for gene therapy applications. Engineering of the TadA and/or TadA* domain has partly reduced these issues[44,45]. However, the rate of off-target RNA editing rate increases with the deaminase level[46]. We therefore asked whether DIMMER regulation could further reduce off-target RNA editing while preserving high levels of on-target DNA editing without additional protein engineering.

We investigated the impact of ABEMax regulation on both on-target DNA, and off-target RNA editing. To evaluate the on-target editing rate, we designed a guide RNA targeting the widely used “site 3” in HEK293[45,47]. We then co-transfected HEK293 cells with the guide RNA construct along with the ABEMax base editor, either unregulated or regulated with the DIMMER circuit module (**Figure 7A**). We initially chose the 4×18nt miR-L design since it provides an intermediate expression level setpoint. We harvested the cells 72h post-transfection, and extracted genomic DNA and RNA for further measurements.

The regulated ABEMax base editor performed on-target editing at a similar, if modestly decreased, rate compared to the unregulated control (**Figure 7B**). To measure the off-target RNA editing rate, we selected three transcripts (*CTNNB1*, *RSL1D1*, *IP90*) known to exhibit high off-target editing due to similarity with native TadA tRNA substrates[47, 44]. The DIMMER

circuit successfully decreased the mean A-to-I editing rate by 4 to 8.4-fold across the three transcripts (**Figure 7C**). It also reduced the number of detectable A-to-I conversions within the transcript (using a cutoff of 0.1% based on the sequencing results) (**Figure 7D**). At specific adenosines that are highly edited by the unregulated ABEMax, the circuit exhibited dramatically lower (around 10-fold) editing rates (**Figure 7E, Figure S13A-B**). We did not detect off-target genomic DNA editing on the predicted potential endogenous off-target sites with or without DIMMER. These results show that DIMMER regulation can improve the ratio of on- to off-target edits.

The DIMMER circuit also reduced perturbations to the transcriptome. We performed bulk RNA sequencing on cells treated with ABEMax with or without DIMMER regulation. DIMMER reduced transcriptome changes compared with unregulated ABEMax expression (**Figure 7F, Figure S13C**). More specifically, unregulated ABEMax exhibited ~2-fold more differentially regulated genes (adjusted $p<0.05$) compared to the regulated construct. Gene ontology annotation showed that heat shock proteins, DNA damage, and repair-associated proteins were perturbed in both unregulated and regulated ABEMax groups. However, the unregulated ABEMax group produced 89 differentially expressed genes in the 'nucleoplasm and nucleus' category, suggesting a more pervasive impact (**Figure 7F, Figure S13C, Table S4**). Together, these results indicate that DIMMER can improve the specificity of base editors by limiting their expression.

DIMMER circuits can operate in live mouse brains

Monogenic diseases of the central nervous system could potentially be cured by gene replacement therapies[48,49] using recently developed adeno-associated virus (AAV) capsids that deliver genes across the blood-brain barrier[50–52]. However, many therapeutic genes are toxic or deleterious when overexpressed and expression must be maintained over long periods. These considerations underscore the need for controlled, durable cell type specific in vivo expression of transgenes.

To test whether DIMMER circuits could function in vivo in mouse brain, we designed a set of 6 AAV vectors that express H2B-EGFP with or without the broadly dosage compensating 4×19nt DIMMER circuit (**Figure 7G upper panel, Figure S14A**), For in vivo expression, we compared three promoter systems with distinct cell-type specificities: the CaMKIIα promoter (CaMKIIα hereafter), which drives expression in excitatory projection neurons, particularly in the cortex and hippocampus[53,54]; a hybrid CMV enhancer–MeCP2 promoter (MeP hereafter), which enables broad neuronal expression throughout the brain[55]; and a minimal β-globin promoter driven by the mDLX2 enhancer (mDLX2 hereafter), which selectively targets GABAergic interneurons in the forebrain, including the motor cortex[56]. As controls, we also delivered a corresponding set of unregulated constructs lacking the DIMMER circuit. All constructs were codelivered with the mRuby3 construct for internal normalization. We injected each pair of constructs into one cohort of mice, and analyzed expression of both fluorescent reporters over time by two-photon head-fixed imaging at single-cell resolution through a previously described cranial implant[57] over the left motor cortex (**Figure 7G lower panel, Methods**). This approach allowed us to monitor the fluorescent dynamics of EGFP and mRuby3 expression in individual cortical cells over timescales of 56-84 days.

To better understand the relationship between promoter strength, expression dynamics, and regulatory compensation, we analyzed circuit performance over time (**Figure S14B-E**). For all three promoters, fluorescence gradually accumulated over multiple weeks. Notably, the mDLX2 promoter, which is relatively weak and interneuron-specific, showed no evidence of dosage compensation across all timepoints (**Figure S14D**). Similarly, the MeP promoter, which drives moderate, pan-neuronal expression, shifted the distribution downward in regulated conditions but did not reach expression levels sufficient to trigger compensation, even at later time points (**Figure S14E**). In contrast, the strong CaMKIIα promoter exhibited dosage compensation at later stages (28–56 days). By 28 days, expression from the regulated CaMKIIα construct plateaued and diverged from the unregulated condition, consistent with engagement of post-transcriptional attenuation by the DIMMER circuit (**Figure 7H, S14B**). These findings suggest that dosage compensation can occur in the brain for some construct designs, that promoter strength and time-dependent expression dynamics are critical for entering the dosage compensation regime, and that weaker promoters may be unable to reach high enough expression levels to activate compensatory repression with this DIMMER variant (**Figure S14F**). Modulation of circuit parameters such as the numbers of miRNA or target sites copies could allow dosage compensation with weaker promoters.

Discussion

Ectopic gene expression is a cornerstone of modern biology, and gene and cell therapy but precise control has remained elusive in most applications. The miRNA circuits described here achieve precise, sequence-tunable gene dosage-invariant control of protein expression (**Figure 2 and 3**), orthogonal control of multiple target genes (**Figure 4**), and portability across cell types and modes of delivery (**Figure 5**). We therefore anticipate that they could become standard systems for controlled gene expression in diverse areas of biomedical science and biotechnology, including imaging (**Figure 6**), CRISPR-based gene editing (**Figure 7**), and AAV-based gene therapy (**Figure 7, Figure S14**).

The process of engineering these circuits revealed unexpected design principles. Strong miRNA regulation, as obtained with the 1×21nt circuit, was not sufficient for dosage invariance within targeted expression levels (**Figure 1F**). Rather, simultaneously reducing complementarity and multimerizing target sites to engage multivalent TNRC6-dependent regulation was essential. In other regulatory systems, multispecific recognition is associated with ultrasensitivity. Here, however, it allowed linearly sensitive repression of mRNA required for dosage invariance but shifted responses to higher dosages. It will be interesting to learn whether natural miRNA regulatory systems use multispecific binding in similar ways[58,59]. We also observed that separation of miRNA and target gene into divergently transcribed genes can be useful in allowing strong, independent control of miRNA expression relative to target mRNA (**Figure 3B-E**) but is not required for precise expression, facilitating applications like gene therapy where vector capacity can be limiting (**Figure S2**).

The system may be extended or improved in different ways. First, better miRNA sequence-function models could potentially allow predictive design of setpoints. Second, current expression distributions exhibit significant variability, or noise (**Figure 3E**). This could reflect transcriptional bursting of the target or the miRNA, and could also be exacerbated by potential differences in the time delays for miRNA production and processing compared to

RNA splicing and nuclear export. Going forward, understanding these and other contributions to overall variability could help to reveal fundamental limits of expression precision in the cell[4,5,60,61]. Finally, the ability to combine DIMMER regulation with inducible promoters or natural enhancers for cell type specificity could make these systems even more useful.

The circuits introduced here will be useful in diverse settings. They reduced background in imaging applications (**Figure 6**). They also reduced off-target RNA editing by CRISPR base editors, while maintaining on-target editing, suggesting they may be useful for gene editing applications (**Figure 7**). Analysis of stronger circuits with even lower expression setpoints could help to achieve even lower off-target edit rates. A major application category is gene therapy (**Figure 7G-H, Figure S14**). Many monogenic diseases that are gene therapy targets exhibit toxicity at high levels of the therapeutic gene, making it critical to suppress overexpression[62–66]. In the future, DIMMER circuits could also ensure fixed expression levels for receptors or other components in cell therapies[67], and therefore allow expression of transcription factors and other components at physiological expression levels for regenerative medicine and other applications[68,69]. Thus, we anticipate these systems becoming useful components in a wide range of engineered research and therapeutic contexts.

Limitations of the study. The DIMMER circuits have limitations. First, we do not yet have a predictive model of how an arbitrary miRNA sequence will behave quantitatively in a dosage compensation circuit. Varying miRNA regulation strength by modulating complementarity was straightforward with miR-L, but more complex for other synmiRs, suggesting that additional factors besides base pairing are likely important for fully predicting the activity of a miRNA on its target. Second, some aspects of the relevant molecular mechanisms remain unclear, including the role of catalytic slicer-dependent regulation[70,71].

Resource availability

Raw and analyzed data associated with this paper have been deposited at CaltechDATA (data.caltech.edu) and will also be shared by the corresponding author upon request. The link to the CaltechDATA page is https://data.caltech.edu/records/e2fjt-agg74.

Acknowledgements

We thank Phillip Zamore (UMass), Josh Mendell (UT Southwestern Medical Center), Acacia Mayfield, James Linton, Kaiwen Luo, Martin Tran, Duncan Chadly, Shiyu Xia, Yodai Takei, Felix Horns, Lucy Chong, Leah Santat, Sheng Wang for discussion and technical support; Inna-Marie Strazhnik (Caltech) for graphical design; Fei Chen (Broad Institute), Rui Malinowski, Evan Mun, Judy Shon, Jacob Parres-Gold, and other members of the Elowitz lab for critical feedback, and administrative support. This work is supported by the National Institute Of Biomedical Imaging And Bioengineering of the National Institutes of Health under Award Number R01EB030015. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. M.B.E. is a Howard Hughes Medical Institute Investigator. We apologize for incomplete citations due to space limits.

Author contributions

R.D., M.F., and M.B.E. conceived and designed the study. M.B.E. directed and supervised the study. R.D., M.F., K.M., M.H., B.G., D.L., and S.E.M. performed or assisted with experiments and data analysis. R.D. and M.B.E. wrote the manuscript with input from all authors.

Declaration of interests

Patent applications related to this work have been filed by the California Institute of Technology (US application numbers CIT-9070-P/CIT-9070-P2). M.B.E. is a scientific advisory board member or consultant at TeraCyte, Plasmidsaurus, Asymptote Genetic Medicines, and Spatial Genomics. V.G. is a co-founder and member of the board of directors of Capsida Therapeutics, a fully integrated AAV engineering and gene therapy company. The remaining authors declare no competing interests.

Supplemental information

Table S1-S4
Figure S1-S14
Supplementary Modeling Text

Figure legends

Figure 1. miRNA incoherent feedforward circuits enable dosage-invariant gene expression.
(A) An ideal gene expression system generates uniform protein expression (right panel, uniform green gradient) levels despite variable gene dosage delivered (left panel, variable blue gradient in the nucleus).
(B) An ideal system would enable tunable **(①)**, orthogonal **(②)** control of the target and operate in multiple cell contexts **(③)**. **(②)** shows the protein expressions of two genes of interest regulated by four combinations (indicated by different colors) of two independently-controlled, tunable dosage compensators, with the ellipses indicating the majority of protein expression profile, and the dashed line indicating the centroids of expression.
(C) The architecture of the incoherent feedforward loop (IFFL), top panel. The simplified miRNA-based IFFL circuit architecture, bottom panel.
(D) The minimal model of miRNA inhibition. Upper panel, reactions in the miRNA-mediated regulation, see also **Supplementary Modeling Text**. Lower panel, the minimal model shows that miRNA-mediated regulation enables dosage compensation compared to the unregulated control.
(E) The circuit configuration of the miRNA-mediated IFFL. Various target-miRNA complementarity and target site numbers were experimentally explored to implement dosage compensation. See also **Figure S2**.
(F) A single, fully complementary miR-L site (1×21nt) shows strong repression compared to the unregulated but does not achieve dosage compensation. mRuby control shows the bleed-through signal from mRuby3 in the EGFP channel. Cells are gated and binned by mRuby3 intensities. Each dot corresponds to the geometric mean fluorescence intensity of mRuby3 bin breaks and median fluorescence intensity of EGFP in the bin. Shaded regions represent geometric standard deviation.
(G) Reducing the complementarity (the pairing length starting from the seed region) of the single-site target weakens the repression but does not achieve dosage compensation.
(H) Multimerizing the 17nt site restores the repression and achieves dosage compensation at four repeats.
(I) A zoom-in of the 4×17nt in **(H)**. p.d.f, probability distribution function, which measured the distribution of mRuby3 fluorescence intensity. The gray and light gray rectangles indicate the dosage range where the fluorescence intensity of EGFP does not change or change by 4-fold, respectively. The dashed lines with slope=0 or slope=1 indicate the linear dosage dependence at low dosage or dosage independence at high dosage, respectively.

Figure 2. TNRC6 and Ago2 play key roles in regulation of multimerized weak targets.
(A) T6B peptide competitively inhibits TNRC6-dependent regulation (schematic).
(B, C) T6B expression suppresses miR-L-mediated regulation of the 4×17nt construct **(B)** but not the 1×21nt **(C)** construct. Cells were co-transfected with the miR-L-mediated IFFL construct, either with the T6B-peptide or the iRFP as a control.
(D, E) Ectopic wild type Ago2 ($Ago2^{WT}$) suppresses inhibition of 4×17nt **(D)** but not 1×21nt **(E)** constructs.
(F, G) Dominant negative Ago2 ($Ago2^{DN}$) expression suppresses regulation of both 4×17nt **(F)** and 1×21nt **(G)** constructs. In **D-G**, cells were co-transfected with indicated miR-L-mediated IFFL constructs, with either $Ago2^{WT}$ **(D,E)**, $Ago2^{DN}$ **(F,G)**, or a filler plasmid.
(H) Design of synthetic miR-L cassettes without (top) or with (bottom) central mismatches in the passenger strand.
(I, J) Ectopic $Ago2^{WT}$ or $Ago2^{DN}$ modulate miR-L^{mut}-mediated regulation of the 4×17nt **(I)** and 1×21nt **(J)** constructs.
(K, L) The effect of the T6B/$Ago2^{WT}$/$Ago2^{DN}$ overexpression in the miR-L^{mut}-mediated regulation for the 4×18nt **(K)** and 4×19nt **(L)** constructs.
(M) TNRC6 and Ago2 play important roles in dosage compensation (schematic).
See also **Figure S3**.

Figure 3. Dosage-invariant expression levels can be tuned.
(A) Expression levels exhibit biphasic dependence on complementarity. All circuits have 4 miR-L target sites. Expression (y-axis) represents median EGFP fluorescence intensity in cells with mRuby3 fluorescence intensity > 5×10^4, see also the shaded region in the right panel). Right panel, the dosage response curves of the five selected constructs (dashed boxes) in the left panel.
(B) Complementarity of 17-19nt monotonically regulates setpoint (black horizontal line). See also **Figure S4**.
(C) Number of miR cassettes fine-tunes setpoint (black horizontal line).
(D) miR-L promoter strength regulates setpoint (black horizontal line). Bars indicate mRuby3 median fluorescence intensities of transfected cells. In C and D, the target is 4×17nt.
(E) Tet system allows tunable dosage compensation. Left panel, design of the inducible DIMMER. A CMV promoter harboring two downstream TetO sites was utilized to drive 4-epi-Tc inducible expression in the TRex cell line. Right panel, the performance of the inducible 4×19nt DIMMER construct. The concentrations of the drug, from purple to yellow, were 0, 10, 33.3, 100, 333.3 ng/mL. The gray curve denotes the mRuby-only transfection control. See also **Figure S5**.

Figure 4. Orthogonal dosage compensation circuits allow independent control of target genes.
(A) Open loop system allows simultaneous readout of miRNA expression (BFP) and its effect on target gene expression (EGFP), at different target gene dosages (mRuby3).
(B) Open loop circuits reveal quantitative miRNA input-output relationship. Cells were co-transfected with the 1×21nt target, either with the miR-L construct shown in **(A)**, or mTagBFP2 as a control. Relative expression was defined as the median of the ratio of EGFP fluorescence intensity to mRuby3 fluorescence intensity in each mTagBFP2 bin. Dots and shaded regions are as described in **Figure 1F**.
(C) synmiRs use a simple empirical design algorithm.
(D) All synmiRs are capable of regulating cognate target genes. Open loop response curves are divided into plots for clarity. Each plot shows regulation of a target incorporating a single 21nt target site.
(E) The 10 synmiRs function orthogonally. Cells were co-transfected with each combination of target and miRNA for open loop analysis. Relative expression levels were quantified as described in **(B)**, and normalized by maximal expression of each construct across synmiRs. Biological replicates shown in **Figure S6C**.

(F) synmiRs can generate dosage compensated regulation. Each construct has the indicated target repeat number and complementarity.
(G) Two DIMMER constructs can be analyzed in the same cells using distinct fluorescent proteins. Diagrams depict double DIMMER reporter systems.
(H) The double DIMMER reporter system allows independent regulation of two genes in four distinct expression configurations. Cells were poly-transfected with the double DIMMER reporter system for DIMMER combinations shown in **(G)**. Data were gated by mRuby3 and mTagBFP2 intensities. Specific DIMMER circuits are indicated in legend (right). Solid contour lines indicate regions containing 80% of cells. Profile plots show the distributions of the corresponding fluorescent proteins. See also **Figure S6-S8**.

Figure 5. Dosage compensation systems are portable and minimally perturbative.
(A) DIMMERs function in multiple cell lines. 4×17nt DIMMER circuits were analyzed in indicated cell lines. Minimal dosage for the compensation regime (threshold level) and setpoint expression were indicated by gray vertical lines and horizontal lines, respectively.
(B) The threshold and the saturating level co-vary across cell lines. The black solid line indicates a linear fit in the log-log space (**Methods**).
(C) iON transposition was used to genomically integrate DIMMER circuits to prepare clonal stable lines (right).
(D) DIMMER circuits enable uniform protein expression (y-axis) across a range of stable integrations and expression levels (x-axis). Each color shows the 4×17nt DIMMER (left panel) compared with the unregulated construct (right panel) in PiggyBac-integrated monoclonal U2OS cells. Profile histograms show the mRuby3 and the EGFP distributions of each mono-clone.
(E) DIMMER circuits show limited perturbation to the endogenous transcriptome. Bulk RNAseq volcano plots of the cells transfected with either the synmiR-3 (orange and red dots) or synmiR-L (light blue and dark blue dots), compared to mTagBFP2-only transfected cells. Dashed lines indicate $|\log_2(\text{fold change})| = 2$. Red dashed line indicates adjusted p-value = 0.05. The Venn diagram shows differentially expressed genes between synmiR-3 and synmiR-L.
(F) Global mRNA expression levels, measured in normalized transcripts per million (TPM), of the miR-L expressing cells plotted against those of the synmiR-3 expressing cells. Solid line indicates equal expression in both samples. Dashed lines indicate 10-fold expression differences. See also **Figure S9-10**.

Figure 6. Dosage compensation circuits enhance biological imaging.
(A) EGFR receptor fusions to mEGFP were expressed with (lower panel) or without (upper) regulation.
(B) Illustration of EGFR in the cell membrane (adapted from PDB 7SYE). EGFR is linked to an mEGFP labeled with a DNA-conjugated anti-GFP nanobody (PDB 6LR7).
(C) Diffraction-limited and DNA-PAINT imaging of CHO-K1 cells expressing EGFR-mEGFP. The right panel shows the zoom-in of the boxed area.
(D) Representative single-molecules images of EGFR-mEGFP using DNA-PAINT. Images show (L-R) unregulated or regulated with a series of DIMMER variants.
(E) DIMMER circuits homogeneously reduce expression levels to near-background levels. The empirical cumulative distribution function (ECDF) of the receptor density for the CHO-K1 cells transfected with EGFR-mEGFP with or without the DIMMER module (blue curves), and the endogenous EGFR density in the U2OS cells (green curve), along with the mock-transfected CHO-K1 cells, measured by DNA-PAINT. Receptor densities were: unregulated: 79.0 ± 42.4 μm^{-2}, 4×17nt: 5.1 ± 1.7 μm^{-2}, 4×18nt: 2.8 ± 1.0 μm^{-2}, 4×19nt: 1.7 ± 0.5 μm^{-2}, mock transfection: 0.9 ± 0.2 μm^{-2}, U2OS: 9.8 ± 1.5 μm^{-2} (mean ± 95% confidence interval).
(F) Reducing unregulated plasmid concentration does not provide a low and homogeneous receptor density, measured by DNA-PAINT. The density of the receptors are: 0 ng: 2.5 ± 0.4 μm^{-2}, 125 ng:

36.0 ± 25.0 μm^{-2}, 250 ng: 115.7 ± 74.4 μm^{-2}, 500 ng: 104.1 ± 64.5 μm^{-2}(mean ± 95% confidence interval).
See also **Figure S11**.
(G) dCas9 can be used to image telomeres (schematic). gRNA is driven by a U6 promoter, targeted to the telomeres, and expressed from the same vector as dCas9-EGFP.
(H) DIMMER circuits enable telomere imaging. Upper panel: representative fluorescence images of dCas9-EGFP with or without the DIMMER module. Color bars indicate measured fluorescence intensities. Lower panel, quantitation of the relative signal intensity of the dots in the cells transfected with the dCas9-EGFP with or without the DIMMER module. Each line represents one dot. In the unregulated condition, high backgrounds made isolated dots rare.
See also **Figure S12**.

Figure 7. DIMMERs reduce ABEMax off-target RNA base editing and transcriptome stress, and operate in live mouse brains.
(A) The ABEMax base editor was expressed with or without the miR-L-based DIMMER. The gRNA targeting HEK293 site 3 is expressed on a separate plasmid driven by the U6 promoter.
(B) DIMMER modestly reduces on-target A-to-G DNA editing efficiency, measured by the percentage of the A6 and A8 edited at the HEK293 site 3.
(C,D) DIMMER strongly reduces off-target RNA editing. Average off-target A-to-I RNA editing percentage **(C)** and the total number of the sequenced adenosines in RNA with A-to-I conversion rate above 0.1% **(D)** for RSL1D1, CTNNB1, and IP90 across their transcripts. Fold changes show the decrease in off-target editing between the unregulated and the 4×18nt circuit-regulated group.
(E) DIMMER strongly reduces off-target A-to-I RNA editing percentage of four specific A sites in the RSL1D1 transcript (cf. **Fig. S13**). In B-E, each dot is a biological replicate, and error bars denote standard deviation.
(F) DIMMER reduces off-target transcriptome perturbation. Bulk RNAseq of cells containing regulated (4×18nt) and unregulated ABEMax compared to mock transfection. Black dashed lines indicate $|\log_2(\text{fold change})|=0.5$. The red dashed line indicates an adjusted p-value of 0.05. Dots of each group are shown with randomized z-order. Data represent three biological replicates.
(G) AAV-delivered constructs enable comparison of DIMMER-regulated and unregulated expressions in the mouse brain. Upper panel: H2B-EGFP was expressed with or without the miR-L-based regulation. Both unregulated and regulated groups use the same tissue-specific promoters or enhancers (**Methods**). The H2B-mRuby3 uses the same promoter, and serves as the dosage indicator. The H2B-mRuby3 construct and the H2B-EGFP construct (either unregulated or regulated) were co-transfected in the in-vitro cultured cell lines, or were co-delivered to live mouse brains. Lower panel: Two-photon microscopy experiments were performed to quantify circuit dynamics in live mice brains. The detailed surgery and the imaging procedures are described in **Methods**.
(H) In vivo brain expression in the CaMKIIα promoter cohort (unregulated and regulated, respectively) measured by microscope. Data were pooled, binned and plotted based on mRuby3 fluorescence intensities on logarithmic (left) or linear (right) scales. See also **Figure S14**.

Methods

Plasmids construction

Constructs used in this study are listed in **Table S1**. Some constructs were generated using standard cloning procedures. The inserts were generated using PCR or gBlock synthesis (IDT) and were ligated either by T4 ligase (NEB #M0202M) or In-Fusion (Takara #102518) assembly with backbones that are linearized using restriction digestion. The rest of the constructs were designed by the authors and synthesized by GenScript. Selected constructs will be deposited at Addgene and the maps are available.

miRNA alignment to the database

Each synthetic miRNA sequence (mature miRNA, 22 nt) is aligned to the known miRNA sequence database[72–79] (https://mirbase.org/) to identify if there are any similarities existing between the synthetic sequences and the natural sequences.

Tissue Culture

U2OS cells, T-Rex cells, CHO cells, and N2A cells were cultured at 37°C in a humidity-controlled chamber with 5% CO2. The growth media consisted of DMEM (Dulbecco's Modified Eagle Medium, ThermoFisher #11960-069) supplemented with 10% FBS, 1 U/ml penicillin, 1 µg/ml streptomycin, 1 mM sodium pyruvate, 1×NEAA (ThermoFisher #11140-050), 1 mM L-glutamine, and 0.1 mg/mL Normocin (InvivoGen #ant-nr).

Transient Transfection

Cells were seeded at a density of 50,000 cells in each well of a 24 well plate (or at a density of 10,000 cells in each well of a 96 well plate), either standard for flow cytometry or glass-bottom for imaging experiments, and cultured under standard conditions overnight. The following day, the cells were transiently transfected using Fugene HD (Promega #E2311), according to the manufacturer's protocol.

Flow Cytometry

Cells were incubated 2 days after transient transfection, and the culture media was replaced 24 hours post-transfection. Cells were trypsinized with 75 µL of 0.25% trypsin for 5 minutes at 37°C. After digestion, cells were resuspended with 125 µL of HBSS containing 2.5 mg/ml BSA and 1 mM EDTA. Cells were then filtered through a 40 µm cell strainer and analyzed using a CytoFLEX S instrument (Beckman Coulter). We used the FlowJo V10 and self-build python code to analyze the flow data. The regression curves and the confidence intervals in Figure 5B and Figure S9 were computed using the statsmodels.regression.linear_model.OLS package in logarithm spaces.

Cell sorting

To prepare the mono-clones that expressed the genomic-integrated DIMMER circuit, cells were harvested and resuspended in sorting buffer (BD FACS Pre-Sort Buffer) supplemented with 1 U/ml DNAse I by the cell sorter (Sony MA900) as mono-clones. Cells were sorted into 96 well plates in the normal U2OS culture media. Cells were expanded in the 24 well plate before flow cytometry measurement.

In-vitro image analysis

The transiently transfected U2OS/HEK293 cells were imaged using a Nikon confocal microscope at 60× magnification, such that each image was spaced by 0.5 microns in the z-direction. For HEK293 cells, 1 slice in the z-direction was taken given the relatively smaller volume compared to U2OS. Images were processed by the Fiji software[80].

To analyze the relative signal intensity in the dCas9 imaging experiment, maximum intensity projection of 11 slices of the z-stacks were applied. To determine the signal intensity of the dots, freehand lines were drawn to select the dot regions. To determine the signal intensity in the background, ~ 5 micron-long straight lines centering the dots were drawn. The signal intensities were generated by the Fiji ROI mean intensity function. The relative signal intensity is calculated by normalizing the background intensity to be 1.

To analyze the signal to noise ratio (SNR), freehand lines were drawn to select the dot regions and the nucleus regions. The noise intensity was calculated by the intensity in the

nucleus excluding the dots area. The SNR was calculated dividing the mean intensities of each dot by the noise.

Bulk RNA sequencing to identify the off-target effects of the synthetic miRNA on the transcriptome

Sample preparation and sequencing

To verify the off-target effect of all the synmiRs, U2OS cells were plated on 6-well plates with 300,000 cells per well. Cells were transfected the following day with 1,000 ng of either the control plasmid or the BFP-miRNA plasmid using Fugene HD (Promega #E2311) according to the manufacturer's instructions. Media was replaced with 2 mL of fresh media 24 hours post-transfection. Cells were harvested 48 hours post-transfection by digestion with 0.25% Trypsin-EDTA, centrifugation at 300g for 5 minutes, and removal of the supernatant by aspiration. The cell's pellet was stored in -80°C prior to the purification.
RNA was extracted using the RNeasy kit (Qiagen #74106) according to the manufacturer's instructions. RNA was treated with Turbo DNase (ThermoFisher #AM2238) and purified using the RNeasy kit RNA cleanup protocol. mRNA sequencing libraries were prepared by Novogene.

Preprocessing of sequencing data

Reads from the RNA sequencing were aligned to a custom reference genome using kallisto (0.48.0)[81]. This reference consisted of the human genome GRCh38 cDNA (https://github.com/pachterlab/kallisto-transcriptome-indices/releases) and mTagBFP2 coding sequences. Weakly expressed genes were filtered out if they exhibited fewer than 3 samples expressing at least 10 transcripts per million (TPM), or if the maximum TPM among all samples was less than 105. Then, filtered counts were input to DEseq to eliminate the impact of size factors. As the BFP-only cells were used as a reference to evaluate the off-target effect of the miRNAs, genes that showed fluctuating expressions among the three biological replicates of BFP-only cells should be removed from analysis. To achieve this, we computed log(1+x), where x denotes the normalized TPM among the three biological replicates of BFP-only cells. The Fano factors[82,83] of these logarithmic expressions were determined and ranked. Transcripts that ranked as the largest 2.5% in logarithmic Fano factors were eliminated from further analysis. Finally, we computed log(1+x), where x denotes the normalized TPM among all the samples. A difference function was defined to compute the absolute value of the log(1+x) difference between each sample and the untransfected sample. The medians of the difference function of the BFP-only groups and the experimental groups were calculated and used for comparison. The difference between those two difference functions were ranked and similarly, transcripts that ranked as the largest 3% were removed from further analysis.

The Fano factor is defined as:

$$\text{Fano factor} = \frac{\text{variance}(\log(1+x))}{\text{mean}(\log(1+x))}$$

The equation of the difference function is defined as:

$$\Delta(\text{BFP, untransfected}) = |\log(1+x_{\text{BFP}}) - \log(1+x_{\text{untransfected}})|$$

$$\Delta(\text{experimental, untransfected}) = |\log(1+x_{\text{experimental}}) - \log(1+x_{\text{untransfected}})|$$

$$\Delta_{\text{ranked}} = \text{median}(\Delta(\text{BFP, untransfected})) - \text{median}(\Delta(\text{experimental, untransfected}))$$

Differential gene expression analysis

To characterize the perturbations that synthetic miRNA brought to the endogenous transcriptome, differential expression analysis was performed using DESeq2 (1.40.1)[84] in R (4.3.1) comparing transcript counts in miRNA transfected cells and BFP-only cells.

DNA-PAINT

Buffers

The following buffers were used:

- NH_4Cl solution: NH_4Cl (Roth, no. K298.1) was dissolved in ddH_2O for a 2M stock solution, filtered with 0.2µm filter.
- Blocking buffer: 1×PBS, 1 mM EDTA (Thermo Fisher, no. AM9260G), 0.02% Tween-20 (Life Science, no. P7949), 0.05% NaN_3 (Serva, no. 30175.01), 2% BSA (Sigma-Aldrich, no. A9647-100G), 0.05 mg/ml sheared salmon sperm DNA (Life Technologies, no. 15632011), filtered with 0.2µm filter.
- Imaging buffer: 1×PBS, 1mM EDTA, 0.02% Tween-20, 500mM NaCl (Thermo Fisher, no. AM9760G), supplemented with PCA, PCD, trolox, filtered with 0.2µm filter.

PCA, PCD and Trolox. Trolox (100×) was prepared by dissolving 100 mg (±)-6-hydroxy-2,5,7,8-tetra-methylchromane-2-carboxylic acid (trolox; Sigma Aldrich, 238813-5G) in 430µL of 100% methanol (Sigma-Aldrich, 32213-2.5L), 345µL of 1M NaOH (VWR, 31627.290) and 3.2mL of water.

PCD (40×) was made by mixing 154 mg of 3,4-dihydroxybenzoic acid (PCA; Sigma-Aldrich, 37580-25G-F) in 10 ml of water and NaOH and adjusting the pH to 9.0. PCD (100×) was prepared by adding 9.3 mg of protocatechuate 3,4-dioxygenase pseudomonas (PCD; Sigma-Aldrich, P8279) to 13.3 ml of buffer containing 100 mM Tris-HCl pH 8.0 (Thermo Fisher Scientific, AM9855G), 50 mM KCl (Thermo Fisher Scientific, AM9640G), 1 mM EDTA, and 50% glycerol (Sigma-Aldrich, 65516-500ml)).

Cloning. An mEGFP gBlock (obtained from IDT) was inserted into a pcDNA3.1(+) backbone (Thermo Fisher, no.V79020) via Gibson assembly. Two codon-optimized fragments of human EGFR (obtained from IDT) were fused to the mEGFP-pcDNA3.1(+) backbone via Gibson assembly. The plasmid concentration was measured with the NanoDrop One (Thermo Scientific).

Cell culture. CHO-K1 cells (ATCC: CCL-61) were cultured in Ham's F-12K (Kaighn's) medium (Gibco, no. 21127022) supplemented with 10% FBS (Gibco, no. 11573397). U2OS-CRISPR-Nup96-mEGFP cells (a gift from the Ries and Ellenberg laboratories) were cultured in McCoy's 5A medium (Gibco, no. 16600082) supplemented with 10% FBS. All cells were cultured at 37°C and 5% CO_2 and split every 2-3 days via trypsinization using trypsin-EDTA (Gibco, no. 25300096).

Nanobody-DNA conjugation. First, the anti-GFP nanobody (clone 1H1, Nanotag Biotechnologies, N0305) and anti-rabbit IgG nanobody (Nanotag Biotechnologies, N2405) were conjugated to a DBCO-PEG4-Maleimide linker (Jena Bioscience, no. CLK-A108P). After removing the unreacted linker with Amicon centrifugal filters (10,000 MWCO), the DBCO-nanobody was conjugated via DBCO-azide click chemistry to the docking strand (Metabion, see sequence in Table 1). A detailed description of the conjugation can be found in the former work[85].

Fixation of cells. The cells were fixed with 37°C pre-warmed methanol-free 4% PFA (Thermofisher, no. 043368.9M) in 1×PBS for 15 min. Then, the cells were washed 3 times with 1×PBS and then permeabilized with 0.125% TritonX-100 (Sigma Aldrich, no. 93443) in 1×PBS for 2 min. After washing 3 times with 1×PBS, the cells were blocked with the blocking buffer either overnight or for at least 3h at 4°C.

Sample preparation of U2OS cells. 10,000 cm^{-2} U2OS cells were seeded on an ibidi eight-well high glass-bottom chambers (no. 80807). On the next day, the cells were fixed as stated in the fixation protocol and blocked for 3h at 4°C. After washing 3 times with 1×PBS, the primary EGFR antibody (Cell Signaling, clone D38B1, no. 4267) with a dilution of 1:200 in blocking buffer was incubated overnight at 4°C. The next day, the sample was washed 3 times with 1×PBS and 25nM of R2 anti-rabbit NB in the blocking buffer was incubated at RT for 1h. After washing 3 times with 1×PBS, the sample was post-fixed with 4% PFA in 1×PBS for 5 min at RT. The cells were then quenched with 200mM NH_4Cl (Roth, no. K298.1) for 5 min and washed 3 times with 1×PBS. 90nm gold-nanoparticles (Absource, no. G-90-100) in 1:1 in 1×PBS were incubated for 5 min at RT. After washing 3 times with 1×PBS, the cells were washed once with the imaging buffer.

Sample preparation for plasmid dosage measurement. 5,000 cm^{-2} CHO-K1 cells were seeded on an ibidi eight-well high glass-bottom chambers (no. 80807) one day before transfection. The cells were transfected with EGFR-meGFP plasmids with a Thermo Fisher Lipofectamine 3,000 reagent (no. L3000008) with the lower Lipofectamine concentration as indicated by the manufacturer and different plasmid concentrations (0 ng, 125 ng, 250 ng and 500 ng of plasmid per well). After 48h of transfection, the cells were fixed as indicated in the fixation protocol and blocked with blocking buffer for 3h at 4°C. The cells were then post-fixed with 4% PFA and 0.2% glutaraldehyde (Serva, no. 23115.01) in 1×PBS for 10 min. After quenching the sample with 200mM NH_4Cl for 5 min and washing 3 times with 1×PBS. 90 nm gold-nanoparticles in 1:1 in 1xPBS were incubated for 5 min at RT. After washing 3 times with 1×PBS, the cells were washed once with the imaging buffer.

Sample preparation of DIMMER plasmids. 5,000 cm^{-2} CHO-K1 cells were seeded on an ibidi eight-well high glass-bottom chambers (no. 80807) one day before transfection. The cells were transfected with EGFR-mEGFP plasmids with a Thermo Fisher Lipofectamine 3,000 reagent (no. L3000008) with the lower Lipofectamine concentration as indicated by the manufacturer and 250 ng plasmid per well (200µL solution per well and 25µL transfection solution). After 48h of transfection, the cells were fixed as indicated in the fixation protocol and blocked with the blocking buffer for 3h at room temperature (RT). 25nM R3 anti-GFP nanobodies were incubated in the blocking buffer for 1h at RT. After washing 3 times with 1×PBS, the nanobodies were post-fixed with 4% PFA and 0.2% glutaraldehyde in 1×PBS for 10 min. The cells were then quenched with 200mM NH_4Cl for 5 min and washed 3 times with 1×PBS. 90nm gold-nanoparticles (Absource, no. G-90-100) in 1:1 in 1×PBS were incubated for 5 min at RT. After washing 3 times with 1×PBS, the cells were washed once with the imaging buffer and imaged in the imaging buffer.

DNA-PAINT imaging. The samples were imaged in the imaging buffer with the corresponding imager strand (obtained from Metabion, see table 1 for imager strand sequences) for 40k frames with 100ms exposure time per frame and a readout rate of 200 MHz.

Microscope setup. The samples were measured on inverted total internal reflection fluorescence (TIRF) microscopes (Nikon Instruments, Eclipse Ti2) which are equipped with an oil-immersion objective (Nikon Instruments, Apo SR TIRF ×100/numerical aperture 1.49, oil) and a perfect focusing system. The mRuby3 signal was bleached by the 560 nm laser (MPB Communications, 1 W) by using Highly inclined and laminated optical sheet (HILO) illumination. Afterwards, the TIRF mode was established. The Cy3B-conjugated imagers were excited with the 560 nm laser. The laser beam was cleaned with a filter (Chroma Technology, no. ZET561/10) and coupled into the microscope with a beam splitter (Chroma Technology, no. ZT561rdc). The fluorescent signal was filtered with an emission filter (Chroma Technology, nos. ET600/50m and ET575lp) and projected onto a sCMOS camera (Hamamatsu Fusion BT) without further magnification. The camera's central 1152×1152 pixels (576×576 pixels after binning) were used as the region of interest, with a resulting effective pixel size of 130nm. The raw microscopy data was acquired via µManager (Version 2.0.1).

DNA-PAINT analysis. Obtained fluorescent data was reconstructed with Picasso software[35]. The data was first drift-corrected with redundant cross-correlation, after that with picked gold particles as fiducials.

In order to determine the receptor density, a homogeneous area of the cells was picked and the DNA-PAINT data was clustered with the SMLMS clustering algorithm of Picasso[35,86].

The identified cluster centers were used to calculate the measured receptor density per μm^2 (number of cluster centers per area). Given that the labeling efficiency (LE) of the binders to their targets was less than 100%, a correction factor was applied to account for incomplete labeling. The EGFR receptor density was calculated by multiplying the measured receptor density with the LE of the respective binders. The LE values of the binders were determined as previously described in the former work[87]. Specifically, the LE of the anti-GFP nanobody was determined to be 37%, while the LE of the EGFR antibody was 71%.

Statistical testing. To test the statistical significance of the determined receptor densities, we performed the Mood's median test. Mood's median test is a non-parametric statistical test which tests whether the median of two groups are statistically different. Our statistical tests were performed with a custom python script using functions from the scipy.stats module[88].

Table 1 DNA sequence of docking strands and imager strands.

Sequence name	Docking strand sequence (5' to 3')	Imager strand sequence (5' to 3')
R2	ACCACCACCACCACCACCA	TGGTGGT-Cy3B
R3	CTCTCTCTCTCTCTCTCTC	GAGAGAG-Cy3B

Base editor experiment

Transfection and Sample collection

HEK293 cells were seeded at the density of 150k/well in the 24-well plate one day before the transfection. For each well, 750 ng ABEMax base editor plasmid and 250 ng sgRNA plasmid were co-transfected using Fugene HD (Promega #E2311), according to the manufacturer's protocol. Cells were harvested 72 h post-transfection.

Amplicon sequencing and data analysis

To quantify the on-target base editor editing rate, cells were sorted based on the constitutively-expressing mRuby on the base editor plasmid and EGFP on the sgRNA plasmid. Genomic DNA was extracted using Qiagen DNeasy kit (cat. nos. 69504) according to the manufacturer's protocol. The genomic DNA amplicons were amplified using the primer in the reference[47], with the adaptor sequence on each end. Amplicons were size-verified by DNA electrophoresis, purified by the Qiagen gel purification kit, and sequencing was performed by Genewiz Amplicon-EZ (150-500bp) service. The on-target editing rates were analyzed using the online tool CRISPResso2[89].

To quantify the off-target base editor editing rate on the genome, genomic DNA was extracted, and amplicons were obtained using the potential genomic DNA off-target loci-targeted primers reported previously[47]. To quantify the off-target editing on the RNA level, the total RNA was extracted from the cell using the Zymo Direct-zol RNA miniprep kit, according to the manufacturer's protocol. cDNA samples were prepared using the Maxima H Minus First Strand cDNA Synthesis Kit (Thermo Scientific). Amplicons were obtained using the potential RNA off-target-loci-targeted primers reported previously[47]. The amplicons were then size-verified by DNA electrophoresis, purified with the Qiagen gel purification kit, barcoded with the Illumina Miseq 16S Metagenomic sequencing index primers, and further purified with the magnetic NGS beads (Omega Bio-Tek). Library was quantified and normalized with the Qubit fluorometer. Library was then denatured and sequenced with Element AVITI System Sequencing Instrument using AVITI 2×150 Sequencing Kit Cloudbreak (Catalog # 860-00013). The off-target editing rates were analyzed using the online tool CRISPResso2[89].

Bulk RNA sequencing and data analysis

Bulk RNA sequencing

- To analyze the transcriptome-wide perturbation of the base editor, total RNA was extracted from the cells with the Zymo Direct-zol RNA miniprep kit (lot # R2050). 50 ng of extracted mRNA from each sample were used as inputs for downstream NGS library preparation.
- mRNA-seq libraries were prepared in 96-well format with a modified 3'Pool-seq protocol[90]. In brief, reverse transcription reaction were prepared by mixing input RNA with 1 µl Indexed RT Primer (10 µM), 1 µl 10 mM dNTP Mix (New England Biolabs Cat# N0447S),1 µl diluted ERCC Spike-In Mix 1 (0.004 µL stock ERCC per µg RNA, ThermoFisher Cat# 4456740), 3.6 µl of 5×RT buffer (ThermoFisher Cat# EP0752), 0.5 µl of RNAse inhibitor (Thermofisher Cat# EO0381), 1 µl Maxima RT H minus (Thermofisher Cat# EP0752), 2.5 µl 10 uM Template Switching Oligo into a 18 µl reaction. Reverse transcription was carried out in a thermocycler with a program described in 3'Pool-seq protocol.

- Samples from each row of 96-well plate were pooled (column pooling) by mixing an equal volume of each Reverse Transcription reaction into a new well at a total volume of 20 µl. Residual primers were then degraded with the addition of 1 µl Exonuclease I (New England Biolabs) and incubated at 37 °C for 45 min followed by denaturation at 92 °C for 15 min. Subsequent cDNA amplification, tagmentation, and row pooling was performed following 3'Pool-seq protocol.
- Finally, 20 µl of pooled NGS library were subject to Gel-based size selection using E-Gel EX Agarose Gel (ThermoFisher Cat# G401001) to enrich for fragments with size range between 200-1000 bp and eluted in 15 µl.
- Eluted pooled NGS libraries were examined in an Agilent TapeStation 4200 (Agilent Technologies) to determine average fragment sizes. Library concentration was quantified in a Qubit 3.0 Fluorometer (Life Technologies). NGS library molarity was then calculated using 660 g/mol per base-pair as a molecular weight. NGS libraries were diluted to 2 nM, denatured in 0.2N NaOH, and loaded onto Element AVITI sequencer following Element Biosciences Cloudbreak Sequencing user guide.

Data analysis

- Weakly expressed genes were filtered out if they exhibited fewer than 3 samples expressing at least 10 transcripts per million (TPM). Differential expression analysis was performed using DESeq2 (1.40.1)[84] in R (4.3.1). Identified significantly differentially expressed genes were eliminated from further analysis if they were identified among the unregulated, regulated, and untransfected groups with the same trend, which indicates that these genes tend to be expressed as more similar profiles among the base editor-transfected groups and the WT group, thus very likely to be the artifact of the filler-plasmid expression. GO annotation was performed using the DAVID web server (https://david.ncifcrf.gov/).

DNA-FISH imaging

To cross-validate the success of DIMMER-regulating dCas9 labeling the telomeres, Nikon 2 Multipoint acquisition was used to record the absolute coordinates of the fields of view. After the live cell imaging, the plate was removed from the scope and DNA-FISH was performed. Dye-conjugated probes designed to bind to the distal telomeric regions of the chromosome were used following the previously reported protocol[91,92]. The plate was then loaded on the scope, and the recorded coordinates were retrieved. The exactly same fields of view were matched by eye around the recorded coordinates.

DIMMER circuit dynamical quantitation in mice cranial window

AAV Viral Production

All constructs were cloned using the cloning strategy described above. The viral titers of the viruses used in this study were:

Group	**Cargo**	**Viral Titers**
CaMKIIα_unregulated	CAP-B10.CaMKIIα.H2B.EGFP.sv40pA	1.06×10^{14}
	CAP-B10.CaMKIIα.H2B.mRuby3.sv40pA	2.12×10^{14}

Group	Cargo	Viral Titers
CaMKIIα_regulated	CAP-B10.CaMKIIα.H2B.EGFP(4×19nt regulated).sv40pA CAP-B10.CaMKIIα.H2B.mRuby3.sv40pA	8.11×10^{13} 2.12×10^{14}
MeP_unregulated	CAP-B22.CMVenhancer.MEP229.H2B.EGFP.sv40pA CAP-B22.CMVenhancer.MEP229.H2B.mRuby3.sv40pA	1.22×10^{14} 4.04×10^{13} 1.94×10^{14}
MeP_regulated	CAP-B22.CMVenhancer.MEP229.H2B.EGFP(4×19nt regulated).sv40pA CAP-B22.CMVenhancer.MEP229.H2B.mRuby3.sv40pA	4.14×10^{14} 9.86×10^{13} 1.94×10^{14}
mDLX2_unregulated	CAP-B10.mDLX2enhancer.H2B.EGFP.sv40pA CAP-B10.mDLX2enhancer.H2B.mRuby3.sv40pA	1.53×10^{14} 1.64×10^{14}
mDLX2_regulated	CAP-B10.mDLX2enhancer.H2B.EGFP(4×19nt regulated).sv40pA CAP-B10.mDLX2enhancer.H2B.mRuby3.sv40pA	7.79×10^{13} 4.98×10^{13} 1.64×10^{14}

CAP-B22 and CAP-B10 are AAV capsids developed in the previous study[51]. The unit of the viral titers is viral genome copies per mL.

Animals

All animals used in this study were approved by the Institutional Animal Care and Use Committee (IACUC) at the California Institute of Technology. Wildtype C57BL female mice (1.5-4 months of age) were ordered from Jackson Laboratories (Bar Harbor, ME, USA) and were used for surgeries, viral injection, and head-fixed imaging. All mice were singly-housed post-operation and for the remainder of the data acquisition in a room with a reverse light cycle (12h – 12h). For all imaging sessions, mice were imaged during the dark phase of their light cycle.

Cranial Window Surgeries

Mice were deeply anesthetized under 1-2% isoflurane and given subcutaneous injections of ketofen (5 mg/kg), buprenorphine (3.25 mg/kg), dexamethasone (2 mg/kg) and saline for analgesia and hydration. A subcutaneous injection of a few drops of bupivacaine was given under the incision site for local analgesia. An incision was performed over the skull and a piece of skin near the left motor cortex was removed to make room for the implant. A circular craniotomy of approximately 3-mm in diameter was drilled over the left motor cortex and centered 1.6-mm anterior and 1.6-mm lateral from bregma. Saline was flushed periodically throughout the drilling over the bone to hydrate and prevent heating. After extraction of the cranial bone, a gelatin sponge soaked in saline was applied over the exposed dura to remove debris and stop any residual bleeding. A small drop of Kwik-sil silicone elastomer was applied over the dura and a 3-mm diameter glass coverslip (#1.5) was implanted over the craniotomy and sealed with dental cement. A custom-made titanium headbar was fixed using cement over the window to allow for later head-fixation during 2-photon imaging. Following surgery, mice were allowed to recover for at least 4-days before beginning habituation to a rotary platter setup.

AAV Vectors and Administration in Mice

AAV packaging, purification, and delivery were performed as described in the earlier study (Challis et al. 2019). Following surgical implants of cranial windows and recovery, mice were anesthetized under 1-2% isoflurane. Intravenous administration of AAVs was performed by injection into the retro-orbital sinus of mice. All vectors were each delivered at a total of 5×10^{12} viral genomes (VG) in a volume of 50 µL per mouse from 2-4 months of age. A total of three cohorts were designed to test for the performance of the DIMMER circuits with different gene-regulatory elements: CMV-enhancer paired with a minimal MeCP2 promoter (CMV enhancer-MEP229), an mDLX2 enhancer paired with a minimal beta-globin promoter (mDLX2-minBglobin), and a CaMKIIα promoter. Each cohort had two groups: One group coexpressing an unregulated H2B-EGFP transgene and an unregulated H2B-mRuby3 transgene, and a regulated group co-expressing a 4×19nt DIMMER regulated H2B-EGFP transgene and an unregulated H2B-mRuby3 transgene. These transgenes were co-delivered separately in their own AAV-capsids. The mRuby3 signal was later used as an internal reference for the EGFP signal for each mouse.

Two-Photon Head-Fixed Imaging and Acquisition

Mice were habituated to the handler's hand for 3 days. Following this, they were head-fixed onto a rotary platter for an additional 3 days to further habituate to the imaging setup. After habituation, mice were imaged over a variable number of days and weeks to capture the progression of EGFP and mRuby3 expression. We used a custom home built 2-photon microscope equipped with a galvo-galvo scanner for imaging. Each imaging session involved acquiring two high-resolution Z-stacks per mouse using a 20X/1.0 NA objective (Zeiss W Plan-Apochromat, Cat. No. 421452-9700-000) with water immersion. Each of these Z-stacks consisted of 10 Z-steps, ranging from 200-250 µm to 300-350 µm below the dura, with each Z-step separated by 10 µm intervals, for a final 100 µm thick Z-stack. Each Z-step was acquired at a scan rate of 1 Hz with a resolution of 256 by 256 pixels and a pixel dwell time of 13 µs for a total of 180 seconds, over an area of 400 µm × 400 µm. Z-steps in each Z-stack were later processed as mean-intensity projected TIF files to generate a single Z-step image. Each Z-stack was first acquired at 940 nm wavelength (EGFP), followed by 1100 nm (mRuby3). The average laser power beneath the objective was maintained across

imaging sessions at 36-37 mW for the 940 nm wavelength and 46-47 mW for the 1100 nm wavelength.

Two-Photon Data Analysis

Two-photon Z-stacks were acquired separately for EGFP and mRuby3 channels and processed independently. Raw data files were segmented into individual z-step movies based on predefined frame intervals using a custom MATLAB script, with each segment saved as a multi-page TIFF file. Motion correction was applied to each TIFF using rigid registration (Kahan et al. 2021), and motion-corrected data were used to generate mean- and maximum-intensity projection images for each z-step. Following motion correction, mean-intensity projection images were flatfield corrected using MATLAB's imflatfield function with a specified radius of 20 pixels to remove uneven illumination artifacts. Corrected images were saved in a dedicated output directory for subsequent analysis. To ensure spatial correspondence between channels, each flatfield-corrected mRuby3 image was aligned to its corresponding EGFP image using normalized cross-correlation, correcting for lateral drift and maximizing overlap between channels.

Cell segmentation was performed on the mRuby3 channel using the Cellpose deep learning-based segmentation algorithm (model type = "cyto", diameter = 9.0 pixels), generating individual cell masks for each z-step image. These masks were saved in both TIFF and NumPy formats and served as a consistent reference for fluorescence quantification across channels. For each z-step, the corresponding mRuby3-derived cell mask was applied to the EGFP image to extract the total EGFP fluorescence per cell by summing the pixel intensities within each ROI. Separately, a dedicated script was used to quantify total mRuby3 fluorescence per cell by applying the same cell mask to the original mRuby3 image for that z-step. Results were saved as per-z-step .csv files, with all individual pixel values archived in cumulative text files for downstream statistical analysis and visualization.

To evaluate single-cell expression and dynamics across time, total EGFP and mRuby3 fluorescence values per cell were aggregated across multiple mice and imaging timepoints. For the CaMKIIα and CMVe-MeCP2 cohorts, z-steps 1, 5, and 10 were selected from each 10-step Z-stack to reduce the likelihood of overcounting the same cells across adjacent planes. For the mDLX2-minβglobin cohort, only z-step 5 was selected.

References

1. Flynn, M.J., Mayfield, A.M.H., Du, R., Gradinaru, V., and Elowitz, M.B. (2024). Synthetic dosage-compensating miRNA circuits allow precision gene therapy for Rett syndrome. bioRxiv. https://doi.org/10.1101/2024.03.13.584179.

2. Franz, K., Singh, A., and Weinberger, L.S. (2011). Lentiviral vectors to study stochastic noise in gene expression. Methods Enzymol. *497*, 603–622.

3. Balasubramanian, S., Matasci, M., Kadlecova, Z., Baldi, L., Hacker, D.L., and Wurm, F.M. (2015). Rapid recombinant protein production from piggyBac transposon-mediated stable CHO cell pools. J. Biotechnol. *200*, 61–69.

4. Singer, Z.S., Yong, J., Tischler, J., Hackett, J.A., Altinok, A., Surani, M.A., Cai, L., and Elowitz, M.B. (2014). Dynamic heterogeneity and DNA methylation in embryonic stem cells. Mol. Cell *55*, 319–331.

5. Maamar, H., Raj, A., and Dubnau, D. (2007). Noise in gene expression determines cell fate in Bacillus subtilis. Science *317*, 526–529.

6. Alon, U. (2007). Network motifs: theory and experimental approaches. Nat. Rev. Genet. *8*, 450–461.

7. Bleris, L., Xie, Z., Glass, D., Adadey, A., Sontag, E., and Benenson, Y. (2011). Synthetic incoherent feedforward circuits show adaptation to the amount of their genetic template. Preprint, https://doi.org/10.1038/msb.2011.49 https://doi.org/10.1038/msb.2011.49.

8. Strovas, T.J., Rosenberg, A.B., Kuypers, B.E., Muscat, R.A., and Seelig, G. (2014). MicroRNA-based single-gene circuits buffer protein synthesis rates against perturbations. ACS Synth. Biol. *3*, 324–331.

9. Yang, J., Lee, J., Land, M.A., Lai, S., Igoshin, O.A., and St-Pierre, F. (2021). A synthetic circuit for buffering gene dosage variation between individual mammalian cells. Nat. Commun. *12*, 4132.

10. Love, K.S., Johnstone, C.P., Peterman, E.L., Gaglione, S., and Galloway, K.E. (2024). Model-guided design of microRNA-based gene circuits supports precise dosage of transgenic cargoes into diverse primary cells. bioRxiv. https://doi.org/10.1101/2024.06.25.600629.

11. Sheu-Gruttadauria, J., and MacRae, I.J. (2018). Phase Transitions in the Assembly and Function of Human miRISC. Cell *173*, 946–957.e16.

12. Bartel, D.P. (2018). Metazoan MicroRNAs. Cell *173*, 20–51.

13. Fellmann, C., Hoffmann, T., Sridhar, V., Hopfgartner, B., Muhar, M., Roth, M., Lai, D.Y., Barbosa, I.A.M., Kwon, J.S., Guan, Y., et al. (2013). An optimized microRNA backbone for effective single-copy RNAi. Cell Rep *5*, 1704–1713.

14. Qiu, L., Wang, H., Xia, X., Zhou, H., and Xu, Z. (2008). A construct with fluorescent indicators for conditional expression of miRNA. BMC Biotechnol. *8*, 77.

15. Elkayam, E., Faehnle, C.R., Morales, M., Sun, J., Li, H., and Joshua-Tor, L. (2017). Multivalent Recruitment of Human Argonaute by GW182. Mol Cell *67*, 646–658.e3.

16. La Rocca, G., King, B., Shui, B., Li, X., Zhang, M., Akat, K.M., Ogrodowski, P., Mastroleo, C., Chen, K., Cavalieri, V., et al. (2021). Inducible and reversible inhibition of miRNA-mediated gene repression in vivo. Elife *10*. https://doi.org/10.7554/eLife.70948.

17. Shin, C., Nam, J.-W., Farh, K.K.-H., Chiang, H.R., Shkumatava, A., and Bartel, D.P. (2010). Expanding the microRNA targeting code: functional sites with centered pairing. Mol Cell *38*, 789–802.

18. Jee, D., Yang, J.-S., Park, S.-M., Farmer, D.T., Wen, J., Chou, T., Chow, A., McManus, M.T., Kharas, M.G., and Lai, E.C. (2018). Dual Strategies for Argonaute2-Mediated Biogenesis of Erythroid miRNAs Underlie Conserved Requirements for Slicing in Mammals. Mol Cell *69*, 265–278.e6.

19. Wang, P.Y., and Bartel, D.P. (2024). The guide-RNA sequence dictates the slicing kinetics and conformational dynamics of the Argonaute silencing complex. Mol Cell *84*, 2918–2934.e11.

20. McGeary, S.E., Bisaria, N., Pham, T.M., Wang, P.Y., and Bartel, D.P. (2022). MicroRNA 3'-compensatory pairing occurs through two binding modes, with affinity shaped by nucleotide identity and position. Elife *11*. https://doi.org/10.7554/eLife.69803.

21. High-Throughput Analysis Reveals Rules for Target RNA Binding and Cleavage by AGO2 (2019). Molecular Cell *75*, 741–755.e11.

22. Michaels, Y.S., Barnkob, M.B., Barbosa, H., Baeumler, T.A., Thompson, M.K., Andre, V., Colin-York, H., Fritzsche, M., Gileadi, U., Sheppard, H.M., et al. (2019). Addendum: Precise tuning of gene expression levels in mammalian cells. Nat. Commun. *10*, 2622.

23. Ameres, S.L., Horwich, M.D., Hung, J.-H., Xu, J., Ghildiyal, M., Weng, Z., and Zamore, P.D. (2010). Target RNA-directed trimming and tailing of small silencing RNAs. Science *328*, 1534–1539.

24. Ha, M., and Kim, V.N. (2014). Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. *15*, 509–524.

25. McGeary, S.E., Lin, K.S., Shi, C.Y., Pham, T.M., Bisaria, N., Kelley, G.M., and Bartel, D.P. (2019). The biochemical basis of microRNA targeting efficacy. Science *366*. https://doi.org/10.1126/science.aav1741.

26. Pontén, J., and Saksela, E. (1967). Two established in vitro cell lines from human mesenchymal tumours. Int. J. Cancer *2*, 434–447.

27. Puck, T.T., Cieciura, S.J., and Robinson, A. (1958). Genetics of somatic mammalian cells. III. Long-term cultivation of euploid cells from human and animal subjects. J. Exp. Med. *108*, 945–956.

28. Graham, F.L., Smiley, J., Russell, W.C., and Nairn, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. *36*, 59–74.

29. Olmsted, J.B., Carlson, K., Klebe, R., Ruddle, F., and Rosenbaum, J. (1970). Isolation of microtubule protein from cultured mouse neuroblastoma cells. Proc. Natl. Acad. Sci. U. S. A. *65*, 129–136.

30. Marchingo, J.M., and Cantrell, D.A. (2022). Protein synthesis, degradation, and energy metabolism in T cell immunity. Cell. Mol. Immunol. *19*, 303–315.

31. Lakatos, E., Salehi-Reyhani, A., Barclay, M., Stumpf, M.P.H., and Klug, D.R. (2017). Protein degradation rate is the dominant mechanism accounting for the differences in protein abundance of basal p53 in a human breast and colorectal cancer cell line. PLoS One *12*, e0177336.

32. Liu, S., Tan, C., Melo-Gavin, C., Mark, K.G., Ginzberg, M.B., Blutrich, R., Patel, N., Rape, M., and Kafri, R. (2021). Large cells activate global protein degradation to maintain cell size homeostasis. bioRxiv, 2021.11.09.467936. https://doi.org/10.1101/2021.11.09.467936.

33. Swovick, K., Firsanov, D., Welle, K.A., Hryhorenko, J.R., Wise, J.P., Sr, George, C., Sformo, T.L., Seluanov, A., Gorbunova, V., and Ghaemmaghami, S. (2021). Interspecies Differences in Proteome Turnover Kinetics Are Correlated With Life Spans and Energetic Demands. Mol. Cell. Proteomics *20*, 100041.

34. Direct Readout of Neural Stem Cell Transgenesis with an Integration-Coupled Gene Expression Switch (2020). Neuron *107*, 617–630.e6.

35. Schnitzbauer, J., Strauss, M.T., Schlichthaerle, T., Schueder, F., and Jungmann, R. (2017). Super-resolution microscopy with DNA-PAINT. Nat Protoc *12*, 1198–1228.

36. Jo, M., Thomas, K.S., O'Donnell, D.M., and Gonias, S.L. (2003). Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem *278*, 1642–1646.

37. Andrews, B., Chang, J.-B., Collinson, L., Li, D., Lundberg, E., Mahamid, J., Manley, S., Mhlanga, M., Nakano, A., Schöneberg, J., et al. (2022). Imaging cell biology. Nat. Cell Biol. *24*, 1180–1185.

38. Chen, B., Gilbert, L.A., Cimini, B.A., Schnitzbauer, J., Zhang, W., Li, G.-W., Park, J., Blackburn, E.H., Weissman, J.S., Qi, L.S., et al. (2013). Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell *155*, 1479–1491.

39. Ma, H., Naseri, A., Reyes-Gutierrez, P., Wolfe, S.A., Zhang, S., and Pederson, T. (2015). Multicolor CRISPR labeling of chromosomal loci in human cells. Proc. Natl. Acad. Sci. U. S. A. *112*, 3002–3007.

40. Ma, H., Tu, L.-C., Naseri, A., Huisman, M., Zhang, S., Grunwald, D., and Pederson, T. (2016). Multiplexed labeling of genomic loci with dCas9 and engineered sgRNAs using CRISPRainbow. Nat. Biotechnol. *34*, 528–530.

41. Wang, H., Nakamura, M., Abbott, T.R., Zhao, D., Luo, K., Yu, C., Nguyen, C.M., Lo, A., Daley, T.P., La Russa, M., et al. (2019). CRISPR-mediated live imaging of genome editing and transcription. Science *365*, 1301–1305.

42. Grünewald, J., Zhou, R., Garcia, S.P., Iyer, S., Lareau, C.A., Aryee, M.J., and Joung, J.K. (2019). Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature *569*, 433–437.

43. Fiumara, M., Ferrari, S., Omer-Javed, A., Beretta, S., Albano, L., Canarutto, D., Varesi, A., Gaddoni, C., Brombin, C., Cugnata, F., et al. (2024). Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat. Biotechnol. *42*, 877–891.

44. Rees, H.A., Wilson, C., Doman, J.L., and Liu, D.R. (2019). Analysis and minimization of cellular RNA editing by DNA adenine base editors. Sci Adv *5*, eaax5717.

45. Li, J., Yu, W., Huang, S., Wu, S., Li, L., Zhou, J., Cao, Y., Huang, X., and Qiao, Y. (2021). Structure-guided engineering of adenine base editor with minimized RNA off-targeting activity. Nat. Commun. *12*, 2287.

46. Zhou, C., Sun, Y., Yan, R., Liu, Y., Zuo, E., Gu, C., Han, L., Wei, Y., Hu, X., Zeng, R., et al. (2019). Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. Nature *571*, 275–278.

47. Neugebauer, M.E., Hsu, A., Arbab, M., Krasnow, N.A., McElroy, A.N., Pandey, S., Doman, J.L., Huang, T.P., Raguram, A., Banskota, S., et al. (2023). Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity. Nat. Biotechnol. *41*, 673–685.

48. Zhou, L., Wang, Y., Xu, Y., Zhang, Y., and Zhu, C. (2024). Advances in AAV-mediated gene replacement therapy for pediatric monogenic neurological disorders. Mol Ther Methods Clin Dev *32*, 101357.

49. Gao, J., Gunasekar, S., Xia, Z.J., Shalin, K., Jiang, C., Chen, H., Lee, D., Lee, S., Pisal, N.D., Luo, J.N., et al. (2024). Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nat Rev Neurosci *25*, 553–572.

50. Chuapoco, M.R., Flytzanis, N.C., Goeden, N., Christopher Octeau, J., Roxas, K.M., Chan, K.Y., Scherrer, J., Winchester, J., Blackburn, R.J., Campos, L.J., et al. (2023). Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain. Nat Nanotechnol *18*, 1241–1251.

51. Goertsen, D., Flytzanis, N.C., Goeden, N., Chuapoco, M.R., Cummins, A., Chen, Y., Fan, Y., Zhang, Q., Sharma, J., Duan, Y., et al. (2022). AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat Neurosci *25*, 106–115.

52. Huang, Q., Chan, K.Y., Wu, J., Botticello-Romero, N.R., Zheng, Q., Lou, S., Keyes, C., Svanbergsson, A., Johnston, J., Mills, A., et al. (2024). An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Science *384*, 1220–1227.

53. Liu, X.B., and Jones, E.G. (1996). Localization of alpha type II calcium calmodulin-dependent protein kinase at glutamatergic but not gamma-aminobutyric acid (GABAergic) synapses in thalamus and cerebral cortex. Proc Natl Acad Sci U S A *93*, 7332–7336.

54. Sík, A., Hájos, N., Gulácsi, A., Mody, I., and Freund, T.F. (1998). The absence of a major Ca2+ signaling pathway in GABAergic neurons of the hippocampus. Proc Natl Acad Sci U S A *95*, 3245–3250.

55. Rastegar, M., Hotta, A., Pasceri, P., Makarem, M., Cheung, A.Y.L., Elliott, S., Park, K.J., Adachi, M., Jones, F.S., Clarke, I.D., et al. (2009). MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy. PLoS One *4*, e6810.

56. Dimidschstein, J., Chen, Q., Tremblay, R., Rogers, S.L., Saldi, G.-A., Guo, L., Xu, Q., Liu, R., Lu, C., Chu, J., et al. (2016). A viral strategy for targeting and manipulating interneurons across vertebrate species. Nat Neurosci *19*, 1743–1749.

57. Cho, J.R., Chen, X., Kahan, A., Robinson, J.E., Wagenaar, D.A., and Gradinaru, V. (2021). Dorsal Raphe Dopamine Neurons Signal Motivational Salience Dependent on Internal State, Expectation, and Behavioral Context. J Neurosci *41*, 2645–2655.

58. Cursons, J., Pillman, K.A., Scheer, K.G., Gregory, P.A., Foroutan, M., Hediyeh-Zadeh, S., Toubia, J., Crampin, E.J., Goodall, G.J., Bracken, C.P., et al. (2018). Combinatorial Targeting by MicroRNAs Co-ordinates Post-transcriptional Control of EMT. Cell Syst *7*, 77–91.e7.

59. Li, C.-J., Liau, E.S., Lee, Y.-H., Huang, Y.-Z., Liu, Z., Willems, A., Garside, V., McGlinn, E., Chen, J.-A., and Hong, T. (2021). MicroRNA governs bistable cell differentiation and lineage segregation via a noncanonical feedback. Mol. Syst. Biol. *17*, e9945.

60. Raser, J.M., and O'Shea, E.K. (2005). Noise in gene expression: origins, consequences, and control. Science *309*, 2010–2013.

61. Pedraza, J.M., and van Oudenaarden, A. (2005). Noise propagation in gene networks. Science *307*, 1965–1969.

62. Van Alstyne, M., Tattoli, I., Delestrée, N., Recinos, Y., Workman, E., Shihabuddin, L.S., Zhang, C., Mentis, G.Z., and Pellizzoni, L. (2021). Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat. Neurosci. *24*, 930–940.

63. Hinderer, C., Katz, N., Buza, E.L., Dyer, C., Goode, T., Bell, P., Richman, L.K., and Wilson, J.M. (2018). Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum. Gene Ther. *29*, 285–298.

64. Smith, S.E.P., Zhou, Y.-D., Zhang, G., Jin, Z., Stoppel, D.C., and Anderson, M.P. (2011). Increased gene dosage of Ube3a results in autism traits and decreased glutamate synaptic transmission in mice. Sci. Transl. Med. *3*, 103ra97.

65. Collins, A.L., Levenson, J.M., Vilaythong, A.P., Richman, R., Armstrong, D.L., Noebels, J.L., David Sweatt, J., and Zoghbi, H.Y. (2004). Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. *13*, 2679–2689.

66. Matagne, V., Borloz, E., Ehinger, Y., Saidi, L., Villard, L., and Roux, J.-C. (2021). Severe offtarget effects following intravenous delivery of AAV9-MECP2 in a female mouse model of Rett syndrome. Neurobiol. Dis. *149*, 105235.

67. Bashor, C.J., Hilton, I.B., Bandukwala, H., Smith, D.M., and Veiseh, O. (2022). Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. *21*, 655–675.

68. Loh, Y.-H., Hartung, O., Li, H., Guo, C., Sahalie, J.M., Manos, P.D., Urbach, A., Heffner, G.C., Grskovic, M., Vigneault, F., et al. (2010). Reprogramming of T cells from human peripheral blood. Cell Stem Cell *7*, 15–19.

69. Wang, H., Yang, Y., Liu, J., and Qian, L. (2021). Direct cell reprogramming: approaches, mechanisms and progress. Nat. Rev. Mol. Cell Biol. *22*, 410–424.

70. Liu, Z., Johnson, S.T., Zhang, Z., and Corey, D.R. (2019). Expression of TNRC6 (GW182) Proteins Is Not Necessary for Gene Silencing by Fully Complementary RNA Duplexes. Nucleic Acid Ther. *29*, 323–334.

71. Kilikevicius, A., Meister, G., and Corey, D.R. (2022). Reexamining assumptions about miRNA-guided gene silencing. Nucleic Acids Res *50*, 617–634.

72. Kozomara, A., Birgaoanu, M., and Griffiths-Jones, S. (2019). miRBase: from microRNA

sequences to function. Nucleic Acids Res. *47*, D155–D162.

73. Kozomara, A., and Griffiths-Jones, S. (2014). miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. *42*, D68–D73.

74. Kozomara, A., and Griffiths-Jones, S. (2011). miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. *39*, D152–D157.

75. Griffiths-Jones, S., Saini, H.K., van Dongen, S., and Enright, A.J. (2008). miRBase: tools for microRNA genomics. Nucleic Acids Res. *36*, D154–D158.

76. Griffiths-Jones, S., Grocock, R.J., van Dongen, S., Bateman, A., and Enright, A.J. (2006). miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. *34*, D140–D144.

77. Griffiths-Jones, S. (2004). The microRNA Registry. Nucleic Acids Res. *32*, D109–D111.

78. Ambros, V., Bartel, B., Bartel, D.P., Burge, C.B., Carrington, J.C., Chen, X., Dreyfuss, G., Eddy, S.R., Griffiths-Jones, S., Marshall, M., et al. (2003). A uniform system for microRNA annotation. RNA *9*, 277–279.

79. Meyers, B.C., Axtell, M.J., Bartel, B., Bartel, D.P., Baulcombe, D., Bowman, J.L., Cao, X., Carrington, J.C., Chen, X., Green, P.J., et al. (2008). Criteria for annotation of plant MicroRNAs. Plant Cell *20*, 3186–3190.

80. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat. Methods *9*, 676–682.

81. Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. *34*, 525–527.

82. Munsky, B., Neuert, G., and van Oudenaarden, A. (2012). Using gene expression noise to understand gene regulation. Science *336*, 183–187.

83. Raj, A., and van Oudenaarden, A. (2009). Single-molecule approaches to stochastic gene expression. Annu. Rev. Biophys. *38*, 255–270.

84. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. *15*, 550.

85. Strauss, S., and Jungmann, R. (2020). Up to 100-fold speed-up and multiplexing in optimized DNA-PAINT. Nat Methods *17*, 789–791.

86. Reinhardt, S.C.M., Masullo, L.A., Baudrexel, I., Steen, P.R., Kowalewski, R., Eklund, A.S., Strauss, S., Unterauer, E.M., Schlichthaerle, T., Strauss, M.T., et al. (2023). Ångström-resolution fluorescence microscopy. Nature *617*, 711–716.

87. Hellmeier, J., Strauss, S., Xu, S., Masullo, L.A., Unterauer, E.M., Kowalewski, R., and Jungmann, R. (2024). Quantification of absolute labeling efficiency at the single-protein level. Nat Methods *21*, 1702–1707.

88. Virtanen, P., Gommers, R., Oliphant, T.E., Haberland, M., Reddy, T., Cournapeau, D., Burovski, E., Peterson, P., Weckesser, W., Bright, J., et al. (2020). Author Correction: SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods *17*, 352.

89. Clement, K., Rees, H., Canver, M.C., Gehrke, J.M., Farouni, R., Hsu, J.Y., Cole, M.A., Liu, D.R., Joung, J.K., Bauer, D.E., et al. (2019). CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol *37*, 224–226.

90. Sholder, G., Lanz, T.A., Moccia, R., Quan, J., Aparicio-Prat, E., Stanton, R., and Xi, H.S. (2020). 3'Pool-seq: an optimized cost-efficient and scalable method of whole-transcriptome gene expression profiling. BMC Genomics *21*, 64.

91. Takei, Y., Shah, S., Harvey, S., Qi, L.S., and Cai, L. (2017). Multiplexed Dynamic Imaging of Genomic Loci by Combined CRISPR Imaging and DNA Sequential FISH. Biophys. J. *112*, 1773–1776.

92. Takei, Y., Yun, J., Zheng, S., Ollikainen, N., Pierson, N., White, J., Shah, S., Thomassie, J., Suo, S., Eng, C.-H.L., et al. (2021). Integrated spatial genomics reveals global architecture of single nuclei. Nature *590*, 344–350.

Figure 1


A
Variable gene dosage
Uniform protein expression
Gene 1
B
① Dosage-invariant expression compensated range
unregulated
tunable range
Gene expression (a.u.)
Dosage (a.u.)
expression level
② Orthogonality
Low
High
Gene 1
Gene 2
③ Portability (similar behavior in multiple cell types)
C
Gene dosage
mRNA
miRNA
Protein
Ideal IFFL
Gene 1
D
Minimal Model
mRNA
miRNA
Complex
k_{on}
k_{off}
k_c
unregulated
regulated
Gene expression ([mRNA]) (non-dimensionalized units)
Dosage (a.u.)
E
miRNA inhibition of mRNA
regulated protein
Ago
miRNA
mRNA
Varying binding site repeats
repeats
Varying complementarity
miRNA
binding site
DNA
divergent promoter
intron with synthetic miRNA (e.g. mRuby)
dosage indicator
regulated gene
synthetic miRNA binding sites
F
Single 21nt target site
unregulated
1×21nt
mRuby control
target expression (EGFP fluorescence, AU)
G
Single target site, varying complementarity
unregulated
17nt
18nt
19nt
20nt
21nt
mRuby control
H
17nt target site varying repeat number
1×17nt
2×17nt
3×17nt
4×17nt
unregulated
dosage indicator (mRuby fluorescence, AU)
I
p.d.f
4×17nt
slope = 0
slope = 1
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)

Figure 2


A
TNRC6: Ago scaffold
TNRC6
Ago
miRNA
T6B: ectopic truncated TNRC6
T6B
miRNA
Ago
B
17nt
×4
unregulated
4×17nt
4×17nt + T6B
target expression (EGFP fluorescence, AU)
C
21nt
×1
unregulated
1×21nt
1×21nt + T6B
dosage indicator (mRuby fluorescence, AU)
D
unregulated
4×17nt
4×17nt + Ago2WT
E
unregulated
1×21nt
1×21nt + Ago2WT
F
unregulated
4×17nt
4×17nt + Ago2DN
G
unregulated
1×21nt
1×21nt + Ago2DN
dosage indicator (mRuby fluorescence, AU)
H
miR-L
CAGGAAUUAUAAUGCUUAUCUAUA
UCCUUAAUAUUACGAAUAGAUAU
guide strand
miR-L central mismatch (miR-Lmut)
CAGGAAUUAUACCGCUUAUCUAUA
UCCUUAAUAUUACGAAUAGAUAU
guide strand
I
miR-Lmut
unregulated
4×17nt
4×17nt + Ago2DN
4×17nt + Ago2WT
J
miR-Lmut
unregulated
1×21nt
1×21nt + Ago2DN
1×21nt + Ago2WT
dosage indicator (mRuby fluorescence, AU)
K
miR-Lmut
unregulated
4×18nt
4×18nt + Ago2DN
4×18nt + Ago2WT
4×18nt + T6B
L
miR-Lmut
unregulated
4×19nt
4×19nt + Ago2DN
4×19nt + Ago2WT
4×19nt + T6B
dosage indicator (mRuby fluorescence, AU)
M
TNRC6
deadenylation
RISC
slicing
mRNA
translation
protein

Figure 3


A
4 × n target
target expression (EGFP fluorescence, AU)
miRNA
complementarity, n
complementarity
4×8nt
4×10nt
4×11nt
4×17nt
4×20nt
dosage indicator (mRuby fluorescence, AU)
B
unregulated
4×17nt
4×18nt
4×19nt
C
1×miR-L
2×miR-L
3×miR-L
D
EF1α
PGK
Promoter strength (mRuby fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)

E
OFF
intron with synthetic miRNA
mRuby
CMV
TetR
TetO
EGFP
miRNA binding site
ON
4-epi-Tetracycline
4-epi-Tetracycline conc.
saturation
0
target expression (EGFPfluorescence, AU)
dosage indicator (mRuby fluorescence, AU)

Figure 4


A
Open loop system
P CMV/EF1α
miRNA expression indicator
intron with synthetic miRNA
BFP
dosage indicator
synthetic miRNA binding sites
mRuby
EGFP
divergent promoter
regulated gene
B
relative expression (EGFP/mRuby)
BFP only
BFP-miRL
miRNA dosage (mTagBFP2 fluorescence, AU)
C
total G/C content: 5-8
extensive 1-2 G/C
supple-mentary
central loop
seed 1-4 G/C
3'-NNNN

Figure 5


A
unregulated
4×17nt
U2OS
CHO
HEK293
N2A
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
B
Saturating Level (EGFP fluorescence, AU)
threshold (mRuby fluorescence, AU)


C
Transposase:
dosage indicator
miRNA
mRuby
inverted direction
synthetic miRNA binding sites
EGFP
divergent promoter
regulated gene
genomic DNA
TTAA
sort mRuby positive cells as mono-clones
enrich
heterogeneous colonies
measure EGFP regulated gene


D
4×17nt
unregulated
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)


E
synmiR-3
synmiR-L
PCSK5
HSPA1A
SPARC
HSPA6
HSPA1B
BFP
GNAS
RPL17
VIM
BFP
-log10 Adjusted p-value
log2 Fold Change


F
BFP
synmiR-L
synmiR-3

Figure 6


A
Unregulated
EGFR-mEGFP
divergent promoter
mRuby
EGFR-mEGFP
Regulated
intron with synthetic miRNA
divergent promoter
synthetic miRNA binding sites
mRuby
EGFR-mEGFP
B
EGFR
extracellular
intracellular
mEGFP
Anti-mEGFP nanobody
Imager
Docking strand
C
diffraction-limited
DNA-PAINT
2 µm
200 nm
D
Unregulated
4×17nt
4×18nt
4×19nt
500 nm
E
ECDF
Receptor Density (µm −2)
Category
unregulated
4×17nt
4×18nt
4×19nt
mock transfect
U2OS
F
ECDF
Receptor Density (µm −2)
Category
0ng
125ng
250ng
500ng
G
divergent promoter
mRuby
dCas9-EGFP
Unregulated
dCas9
EGFP
gRNA
Telomere
Regulated
intron with synthetic miRNA
divergent promoter
synthetic miRNA binding sites
mRuby
dCas9-EGFP
H
Unregulated
4×17nt
4×19nt
20 µm
EGFP expression
Relative Signal Intensity
position (µm)

Figure 7


A
Unregulated
intron with synthetic miRNA
divergent promoter
scrambled miRNA binding sites
mRuby
ABEMax
Regulated (4×18nt)
intron with synthetic miRNA
divergent promoter
synthetic miRNA binding sites
mRuby
ABEMax
gRNA targeting site3
sgHEK-site3
B
On-target DNA editing
On target DNA A-to-G editing efficiency (%)
ABEMax unregulated
ABEMax regulated
Cas9n
WT
A6
A8
C
Off-target RNA editing
Average A-to-I frequency among adenosines within transcript
8.4-fold
5.7-fold
4-fold
RSL1D1
CTNNB1
IP90
D
Off-target RNA editing
Number of sequenced adenosines in RNA with A-to-I conversion >0.1%
RSL1D1
CTNNB1
IP90
E
Off-target RNA editing across RSL1D1 transcript
A-to-I editing percentage at indicated position
A92
A152
A156
A157
Position of adenosine in amplicon
F
Differential Expression, ABEMax vs mock transfection
ABEMax unregulated
ABEMax regulated
-log10 Adjusted p-value
log2 Fold Change
G
Separate constructs of the dosage indicator and the DIMMER-regulated target
Unregulated
promoter
H2B-EGFP
dosage indicator
promoter
H2B-mRuby
Regulated (4×19nt)
promoter
H2B-EGFP
synthetic miRNA binding sites
intron with synthetic miRNA
H
regulated
unregulated
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
1e6
regulated
unregulated
Two-photon microscopy quantifying the circuit dynamics in the live mice brain
AAV capsids
Retro-orbital codelivery
Imaging primary motor cortex (~200 - 350 μm deep)
20×magnification
Head-fixed
Cranial window
10 Z-step intervals

Figure S1


A
Modeling different k_{off}
unregulated
k_{off} = 10
k_{off} = 1 × 10^2
k_{off} = 1 × 10^3
k_{off} = 1 × 10^4
Gene expression ([mRNA]) (non-dimensionalized units)
Dosage (a.u.)
B
Modeling different k_c
unregulated
k_c = 0.4
k_c = 0.004
k_c = 0.0004
Gene expression ([mRNA]) (non-dimensionalized units)
Dosage (a.u.)
C
Modeling different n
unregulated
n = 0.5
n = 1
n = 2
Gene expression ([mRNA]) (non-dimensionalized units)
Dosage (a.u.)
D
Modeling different k_c
unregulated
k_c = 400
k_c = 40
k_c = 4
k_c = 0.4
total mRNA (non-dimensionalized units)
Dosage (a.u.)

Figure S2

1st generation of circuits: co-transcribed miRNA design

① miRNA in the 3'UTR





② miRNA in the 5'UTR



③ miRNA inside the transcript





2nd generation of circuits: separately transcribed miRNA design

① miRNA in the 3'UTR





② miRNA in the 5'UTR





③ miRNA inside the transcript





3rd generation of circuits: co-transcribed miRNA design, optimized splicing sequence

① miRNA in the 3'UTR





Figure S3


A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
unregulated
1×18nt
2×18nt
3×18nt
4×18nt
1×19nt
2×19nt
3×19nt
4×19nt
1×bulge(5nt)
1×bulge(4nt)
1×bulge(3nt)
1×bulge(2nt)
1×bulge(1nt)
4×bulge(5nt)
miRNA
bulged binding site
bulged binding site (5nt)
4×17nt
4×17nt + T6B
4×17nt + T6B^Mut
1×21nt
1×21nt + T6B
1×21nt + T6B^Mut
1×17nt
1×17nt + T6B
2×17nt + T6B
3×17nt + T6B
4×17nt + T6B
1×18nt
1×18nt + T6B
2×18nt + T6B
3×18nt + T6B
4×18nt + T6B
1×19nt
1×19nt + T6B
2×19nt + T6B
3×19nt + T6B
4×19nt + T6B
1×bulge(5nt) + T6B
4×bulge(5nt) + T6B
1×21nt(miR-L^mut)
4×17nt(miR-L^mut)
4×18nt(miR-L^mut)
4×19nt(miR-L^mut)
miR-L^mut

Figure S4


A
B
C
4×8nt
4×10nt
4×11nt
4×17nt
4×20nt
4×9nt
4×12nt
4×13nt
4×14nt
4×15nt
4×16nt
4×21nt
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)

Figure S5


A
4-epi (333.3)
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
4-epi (333.3)
4-epi (100)
4-epi (33.3)
Probability Density
EGFP expression (AU)
B
C
4-epi-Tetracycline conc.
saturation
0
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
D
4×17nt, 4epi 0
4×17nt, 4epi 10
4×17nt, 4epi 33.3
4×17nt, 4epi 100
4×17nt, 4epi 333.3
4×18nt, 4epi 0
4×18nt, 4epi 10
4×18nt, 4epi 33.3
4×18nt, 4epi 100
4×18nt, 4epi 333.3
4×19nt, 4 epi 0
4×19nt, 4 epi 10
4×19nt, 4 epi 33.3
4×19nt, 4 epi 100
4×19nt, 4 epi 333.3
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)

Figure S6


A
B
BFP only
BFP-synmiR-2_initial design
BFP-synmiR-3_initial design
BFP-synmiR-6
relative expression (EGFP/mRuby)
miRNA dosage (mTagBFP2 fluorescence, AU)
C
Target sequence
synmiR-1
synmiR-2
synmiR-3
synmiR-4
synmiR-5
synmiR-7
synmiR-8
synmiR-9
synmiR-10
synmiR-L
miRNA sequence
Relative expression (AU)
D
synmiR-4, 4×17nt
synmiR-5, 4×17nt
unregulated
4×17nt
mRuby control
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
E
synmiR-2_8×8nt, synmiR-L_4×19nt
synmiR-2_8×8nt, synmiR-L_4×17nt
synmiR-5_4×8nt, synmiR-L_4×19nt
synmiR-5_4×8nt, synmiR-L_4×17nt
unregulated
unregulated gene expression ratio (mRuby/mTagBFP2)
Regulated gene expression ratio (EGFP/iRFP)
Regulated Gene 2 [iRFP]
Regulated Gene 1 [EGFP]
Unregulated Gene 2 [mTagBFP2]
Unregulated Gene 1 [mRuby]

Figure S7


A
BFP-synmiR-1
BFP-synmiR-2
BFP-synmiR-3
BFP-synmiR-4
BFP-synmiR-5
BFP-synmiR-7
BFP-synmiR-8
BFP-synmiR-9
BFP-synmiR-10
relative expression (EGFP/mRuby)
miRNA dosage (mTagBFP2 fluorescence, AU)
B
synmiR-1 4×8nt
synmiR-2 8×8nt
synmiR-3 8×16nt
synmiR-4 8×8nt
synmiR-5 8×8nt
synmiR-7 8×12nt
synmiR-8 8×8nt
synmiR-9 4×17nt
synmiR-10 8×8nt
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)

Figure S8


A
synmiR-1
unregulated
4×8nt
4×9nt
synmiR-2
unregulated
4×8nt
4×9nt
8×8nt
synmiR-3
unregulated
4×16nt
8×16nt
synmiR-4
unregulated
4×8nt
8×9nt
8×8nt
synmiR-5
unregulated
4×8nt
8×8nt
4×9nt
4×12nt
synmiR-7
unregulated
4×12nt
8×12nt
synmiR-8
unregulated
4×8nt
4×9nt
8×8nt
synmiR-9
unregulated
4×16nt
4×17nt
4×18nt
synmiR-10
unregulated
8×8nt
8×9nt
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
B
synmiR-1
unregulated
4×8nt
4×8nt + T6B
synmiR-2
unregulated
8×8nt
8×8nt + T6B
synmiR-3
unregulated
4×16nt
4×16nt + T6B
synmiR-4
unregulated
8×9nt
8×9nt + T6B
synmiR-5
unregulated
8×8nt
8×8nt + T6B
synmiR-7
unregulated
8×12nt
8×12nt + T6B
synmiR-8
unregulated
8×8nt
8×8nt + T6B
synmiR-9
unregulated
4×17nt
4×17nt + T6B
synmiR-10
unregulated
8×9nt
8×9nt + T6B
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)

Figure S9


A
U2OS
HEK293
N2A
CHO
target expression
(EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
unregulated
miR-L_4×17nt
synmiR-4_8×9nt
synmiR-5_8×8nt
miR-L_8×8nt
B
saturating level
(EGFP fluorescence, AU)
threshold level (mRuby fluorescence, AU)
U2OS
CHO
HEK293
N2A

Figure S10


Mean
synmiR-1
synmiR-2
synmiR-3
synmiR-4
synmiR-5
synmiR-7
synmiR-8
synmiR-9
synmiR-10
miR-L
BFP

Figure S11


A
unregulated
4×17nt
4×18nt
4×19nt
Probability Density
target expression
(EGFP fluorescence, AU)
B
Unregulated
4×18 nt
8473
6435
4397
2359
321
547
435
323
211
99
20 µm
EGFP expression
C
Unregulated
4×18 nt
55030
41299
27568
13837
106
16841
12711
8581
4451
321
1193
920
646
373
99
467
376
285
194
103
20 µm
D
i
Mood's median test
unregulated
4×17nt
4×18nt
4×19nt
1
2.8e-05
3.9e-07
1.6e-08
2.8e-05
1
0.0091
0.0091
3.9e-07
0.0091
1
0.002
1.6e-08
0.0091
0.002
1
ii
Moods median test
0ng
125ng
250ng
500ng
1
0.031
0.044
0.054
0.031
1
0.45
0.53
0.044
0.45
1
1
0.054
0.53
1
1

Figure S12


A
unregulated
4×17nt
4×19nt
Probability Density
target expression
(EGFP fluorescence, AU)
B
SNR
(Signal to Noise Ratio)
unregulated
4×17nt
4×19nt
Conditions
C
20 μm
D
minimal CMV
promoter
dCas9-EGFP
304
255
206
157
108
20 μm
U2OS
E
DIMMER
4×19nt
193
168
143
118
93
20 μm
HEK293
minimal CMV
promoter
1157
890
623
356
89
20 μm
HEK293
F
minimal CMV promoter
4×19nt
Probability Density
target expression
(EGFP fluorescence, AU)
G
minimal CMV promoter
4×17nt
4×19nt
Probability Density
target expression
(EGFP fluorescence, AU)
H
minimal CMV(112.5 ng)
minimal CMV(75 ng)
minimal CMV(37.5 ng)
minimal CMV(12.5 ng)
4×19nt
Probability Density
target expression
(EGFP fluorescence, AU)

Figure S13


A
Off-target RNA editing across CTNNB1 transcript
A-to-I editing percentage at indicated position
A128
A158
A174
Position of adenosine in amplicon
B
Off-target RNA editing across IP90 transcript
A60
A213
A222
Position of adenosine in amplicon
ABEMax unregulated
ABEMax regulated
Cas9n
WT
C
ABEMax unregulated
ABEMax regulated
Upregulated genes
Downregulated genes
Genes Included
Genes Included by Cluster with Enrichment Score
Nucleoplasm and nucleus
Protein ubiquitination and isopeptide bond
Protein folding, processing, and stress response
Helicase
ATP binding and hydrolysis
Centriole and cilium
Chaperone
Kinetochore and centromere, chromatin segragation
Cell cycle and mitosis
Transcription
Chromosome, DNA damage and repair
Ribonucleoprotein
mRNA processing and splicing
GTP binding
DNA damage, repair, and recombination
Cell cycle and mitosis
ATP binding and hydrolysis
Protein folding, processing, and stress response
Dynein, motor protein, and microtubule
Cilium
ATP hydrolysis and helicase
DNA recombination and chromatin remodeling
ATPase, nucleotide binding domain
Protein ubiquitination and isopeptide bond
Cluster

Figure S14


A
unregulated
4×19nt
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
B
2d
4d
6d
14d
16d
19d
21d
28d
42d
49d
56d
regulated
unregulated
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
C
2R
3R
5N_unregulated
6N_unregulated
relative expression (EGFP/mRuby)
Time (day)
D
mDLX2 promoter-driven GABAergic interneuron expression
regulated
unregulated
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
2R
5R
6L
1N_Unregulated
3L_Unregulated
relative expression (EGFP/mRuby)
Time (day)
E
MeP promoter-driven broad neuronal expression
regulated
unregulated
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)
3L
5RL
7LL
6LL_Unregulated
10L_Unregulated
9R_Unregulated
relative expression (EGFP/mRuby)
Time (day)
F
regulated, mDLX2
regulated, MeP
regulated, CaMKIIα
unregulated, mDLX2
unregulated, MeP
unregulated, CaMKIIα
target expression (EGFP fluorescence, AU)
dosage indicator (mRuby fluorescence, AU)